 
An Exploratory, Open -Label Study of Vedolizumab (anti -47 Monoclonal 
Antibody ) in Subjects with  HIV Infection Undergoing Analytical Treatment 
Interruption  
 
NIAID Protocol Number:  16-I-0118  
 
Sponsored by:  
National Institute of Allergy and Infectious Diseases (NIAID)  
 
 
 
IND Sponsor:  NIAID/OCRPRO  
 
IND #  130343  
 
Medical Monitor: Marc J. Teitelbaum, MD  
 
Principal Investigator:  Michael C. Sneller, M.D.  
 
Draft or Version Number: 5.0 
 
22 March  2017  
 
 
 
 
 
 
Protocol Version 5.0  
22-March -2017 
 
Study Staff Roster  
 
 
 
Principal Investigator :   Michael C. Sneller, MD  
     Laboratory of Immunoregulation  
LIR/NIAID  
     Phone: 301 -496-0491  
     E-mail: msneller@niaid.nih.gov  
 
Associate Investigators:   Anthony Fauci, MD  
     LIR/NIAID  
     Phone: 301 -496-2263  
     E-mail: afauci@niaid.ni h.gov  
 
Tae-Wook Chun, PhD  
     LIR/NIAID  
     Phon e: 301 -496-0890  
     E-mail: twchun@niaid.nih.gov  
 
     Susan Moir, PhD  
LIR/NIAID  
Phone: 301 -402-4559  
E-mail: smoir@niaid.nih.gov  
 
Katherine Clarridge, MD  
LIR/NIAID  
Phone: 301 -496-0890  
     E-mail: katherine.clarridge@niaid.nih.gov  
 
     Avi Nath, MD  
     NINDS  
     Phone:  301 -496-1561  
     E-mail: natha@mail.nih.gov  
 
     Bryan Smith, MD  
     NINDS  
     Phone: 301 -451-4585  
     E-mail:  bryan.smith2@nih.gov  
 
 
 
 
 
 
Protocol Version 5.0  
22-March -2017 
 
Page 3 of 53 
  
 
 
Research Contact    Catherine Seamon, RN CCRP  
     Clinical Center/Critical Care Medicine Department  
     Phone: 301 -402-3481  
     Email: cseamon@cc.nih.gov  
 
Statistician:  Michael Proschan, PhD  
Biostatistics Research Branch/DCR  
Phone: 301-451-5129  
E-mail: proscham@niaid.nih.gov  
 
 
 
Protocol Version 5.0 
22-March-2017  
 
 
Table of Contents 
STUDY STAFF ROSTER ........................................................................................................................  2 
TABLE OF CONTENTS .........................................................................................................................  4 
LIST OF TABLES ................................................................................................................................ . 6 
LIST OF FIGURES ................................................................................................................................  6 
LIST OF ABBREVIATIONS ....................................................................................................................  7 
PROTOCOL SUMMARY ......................................................................................................................  8 
PRÉCIS  ............................................................................................................................................ 10 
1 BACKGROUND INFORMATION AND SCIENTIFIC RAT IONALE ...........................................................  11 
1.1 BACKGROUND INFORMATION  ................................................................................................................ 11 
 Description of the Study Agent  ...............................................................................................  12 
 Summary of Pre -Clinical Nonhuman Primate Studies  ............................................................  13 
 Summary of Relevant Clinical Studies  .....................................................................................  16 
1.2 RATIONALE  ........................................................................................................................................ 19 
2 STUDY OBJECTIVES ...................................................................................................................  19 
2.1 PRIMARY OBJECTIVE  ............................................................................................................................  19 
2.2 SECONDARY OBJECTIVE  ........................................................................................................................  19 
2.3 EXPLORATORY OBJECTIVES  ................................................................................................................... 19 
3 STUDY DESIGN .........................................................................................................................  19 
3.1 DESCRIPTION OF THE STUDY DESIGN  ...................................................................................................... 19 
3.2 STUDY ENDPOINTS  ..............................................................................................................................  20 
 Primary Endpoint  ....................................................................................................................  20 
 Secondary Endpoints ............................................................................................................... 20 
4 STUDY POPULATION .................................................................................................................  21 
4.1 RECRUITMENT PLAN ............................................................................................................................  21 
4.2 SUBJECT INCLUSION CRITERIA  ............................................................................................................... 21 
4.3 SUBJECT EXCLUSION CRITERIA  ............................................................................................................... 22 
4.4 JUSTIFICATION FOR EXCLUSION OF WOMEN , MINORITIES , AND CHILDREN (SPECIAL POPULATIONS ) ................... 23 
5 STUDY AGENT/INTERVENTIO NS ................................................................................................  23 
5.1 DISPOSITION AND DISPENSATION  ........................................................................................................... 23 
 Formulation, Packaging and Labeling  ....................................................................................  23 
5.2 STUDY AGENT STORAGE AND STABILITY  .................................................................................................. 23 
5.3 PREPARATION , ADMINISTRATION , AND DOSAGE OF STUDY AGENT ...............................................................  23 
 Dose Adjustments and Modifications  .....................................................................................  25 
 Duration of Therapy  ................................................................................................................ 25 
5.4 CONCOMITANT MEDICATIONS AND PROCEDURES  .....................................................................................  25 
5.5 PROHIBITED MEDICATIONS AND PROCEDURES ..........................................................................................  25 
6 STUDY SCHEDULE  .....................................................................................................................  25 
6.1 SCREENING  ........................................................................................................................................ 25 
6.2 ENROLLMENT /BASELINE  ......................................................................................................................  26 
Protocol Version 5.0 
22-March-2017  
 
Page 5 of 53 
 6.3 STUDY PHASE (FIGURE 1.1.2-1) ........................................................................................................... 27 
6.4 FOLLOW -UP ....................................................................................................................................... 28 
7 STUDY EVALUATIONS ............................................................................................................... 29 
7.1 CLINICAL EVALUATIONS ........................................................................................................................  29 
7.2 LABORATORY EVALUATIONS  .................................................................................................................. 29 
 Clinical and Research Laboratory Evaluations and Specimen Collection  ...............................  29 
8 POTENTIAL RISKS AND BENEFITS  ...............................................................................................  30 
8.1 POTENTIAL RISKS ................................................................................................................................  30 
8.2 POTENTIAL BENEFITS  ...........................................................................................................................  31 
9 RESEARCH USE OF STORED HUMAN SAMPLES, SP ECIMENS, OR DATA  ........................................ 32 
10 REMUNERATION PLAN FOR SUBJECTS .....................................................................................  32 
11 ASSESSMENT OF SAFETY ......................................................................................................... 33 
11.1 DOCUMENTING , RECORDING , AND REPORT ING ADVERSE EVENTS  ..............................................................  33 
11.2 DEFINITIONS  .................................................................................................................................... 33 
11.3 INVESTIGATOR ASSESSMENT OF ADVERSE EVENTS  .................................................................................. 35 
 Severity  ................................................................................................................................ . 35 
 Causality  ...............................................................................................................................  35 
11.4 INVESTIGATOR REPORTING RESPONSIBILITIES TO T HE SPONSOR  ................................................................ . 36 
 Adverse Events  ......................................................................................................................  36 
 Serious Adverse Events  ......................................................................................................... 36 
 Unanticipated Problems  ....................................................................................................... 36 
 Protocol Specified Events  ...................................................................................................... 36 
 Pregnancy .............................................................................................................................  37 
11.5 INVESTIGATOR REPORTING RESPONSIBILITIES TO T HE NIAID  IRB...............................................................  37 
 Expedited Reporting to the NIAID IRB  .................................................................................. 37 
 Annual Reporting to the NIAID IRB  .......................................................................................  37 
11.6 FOLLOW -UP OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  .............................................................  38 
11.7 SPONSOR’S REPORTING RESPONSIBILITIES  .............................................................................................  38 
11.8 HALTING CRITERIA FOR THE PROTOCOL  ................................................................................................ . 38 
 Reporting of Study Halting  ................................................................................................... 39 
 Resumption of a Halted Study  ..............................................................................................  39 
11.9 PAUSING CRITERIA FOR A SUBJECT  ....................................................................................................... 39 
 Reporting of Pause  ............................................................................................................... 39 
 Resumption of Pausing for a Subject or Group ..................................................................... 39 
11.10  WITHDRAWAL CRITERIA FOR AN INDIVIDUAL SUBJECT  ........................................................................... 40 
11.11  REPLACEMENT FOR WITHDRAWN SUBJECTS  ........................................................................................  40 
11.12  SAFETY OVERSIGHT  .........................................................................................................................  40 
 Safety Review and Communications Plan (SRCP)  ...............................................................  40 
 Sponsor Medical Monitor  ................................................................................................... 41 
12 CLINICAL MONITORING STRUCTURE ........................................................................................  41 
12.1 SITE MONITORING PLAN ....................................................................................................................  41 
13 STATISTICAL CONSIDER ATIONS  ...............................................................................................  41 
14 ETHICS/PROTECTION OF HUMAN SUBJECTS  ............................................................................ 43 
14.1 INFORMED CONSENT PROCESS  ............................................................................................................ 43 
 Non -English–Speaking Participants  ......................................................................................  43 
14.2 SUBJECT CONFIDEN TIALITY  ................................................................................................................. 44 
Protocol Version 5.0  
22-March -2017 
 
Page 6 of 53 
 15 DATA HANDLING AND RE CORD KEEPING  ................................ ................................ .................  44 
15.1 DATA CAPTURE AND MANAGEMENT  ................................ ................................ ................................ .... 44 
15.2 RECORD RETENTION ................................ ................................ ................................ ..........................  45 
APPENDIX A: SCIENTIF IC REFERENCES  ................................ ................................ ..............................  46 
APPENDIX B: SCHEDULE  OF PROCEDURES/EVALU ATIONS  ................................ ................................ . 49 
APPENDIX C: PML CHEC KLIST  ................................ ................................ ................................ ...........  51 
 
 
 
 
List of Tables  
Table 1.1.3 -1. Adverse Reactions in ≥ 3% of Vedolizumab -treated Patients and ≥ 1% 
Higher than in Placebo  ................................ ................................ ............................  17 
Table 13 -1. The second row is the probability of observing at least one adverse event of 
probability given in the first row.  ................................ ................................ ..............  42 
Table 13 -2. The second row gives exact 95% confidence intervals for rebound 
probability given the observed number of rebounders in row 1 among the 20 
patients.  ................................ ................................ ................................ ...................  42 
Table 13 -3.  Futility is declared if the number of patients rebounding by week 30, among 
the number tested in row 1, is at leas t as large as the figure in row 2…….. ..........43 
Table 13 -4.  Row 2 shows the probability of cros sing the futility threshold if the true 30 -
week rebound probability is as shown in row 1.  ................................ .....................  43 
 
List of Figures  
Figure 1.1 .2-1. Nonhuman Primate Trial Design  ................................ ............................  14 
Figure 1.1 .2-2. SIV Plasma Viremia in 47 mAb Tre ated Animals -Trial 1 ...................  14 
Figure 1.1 .3-3. SIV Plasma Viremia in 47 mAb Treated Animals -Trial 2 ...................  15 
Figure 3.1 -1. Study  Design  ................................ ................................ .............................  20 
  
Protocol Version 5.0  
22-March -2017 
 
Page 7 of 53 
 List of Abbreviations  
ADR   Adverse Drug Reaction  
AE  Adverse Event/Adverse Experience  
cART   Combination Antiretroviral Therapy  
CC  Clinical Center  
CD  Crohn’s Disease  
CFR  Code of Federal Regulations  
CIB  Clinical Investigator’s Brochure  
CLIA   Clinical Laboratory Improvement Amendment of 1988  
COI  Conflict of Interest  
CRADA  Cooperative Research and Development Agreement  
CRF  Case Report Form  
CRIMSON  Clinical Research Information Management System of the NIAID  
DCR   Division of Clinical Research  
DSMB   Data and Safety Monitoring Board  
DSMC   Data and Safety Monitoring Committee  
FDA  Food and Drug Administration  
GCP   Good Clinical Practice  
GALT   Gut Associated Lymphoid Tissue  
IB  Investigator’s Brochure  
ICF  Informed Consent Form  
ICH  International Conference on Harmonization  
IND  Investigational New Drug  
IRB  Institutional Review Board  
ISM  Independent Safety Monitor  
IV  Intravenous  
MAb  Monoclonal Antibody  
MRI  Magnetic Res onance Imaging  
N  Number (typically refers to number of subjects/sample size)  
NDA   New Drug Application  
NIAID   National Institute of Allergy and Infectious Diseases  
NIH  National Institutes of Health  
NNRTI   Non-Nucleoside Reverse Transcriptase I nhibitors  
OHRP   Office for Human Research Protections  
OHSRP  Office of  Human Subjects Research Protections  
PBMC   Periphe ral Blood Mononuclear Cells  
PHI  Protected Health Information  
PI  Principal Investigator  
PK  Pharmacokinetics  
PML     Progressive Multifocal Leukoencephalopathy  
QA  Quality Assurance  
QC  Quality Control  
SAE  Serious Adverse Event/Serious Adverse Experience  
SC  SubCutaneous  
SIV  Simian Immunodeficiency Virus  
SMC   Safety Monitoring Committee  
UC  Ulcerative Colitis  
UP  Unanticipated Problem  
UPnonAE  Unanticipated Problem that is not an Adverse Event  
Protocol Version 5.0  
22-March -2017 
 
Page 8 of 53 
 Protocol Summary  
 
Full Title:  An Exploratory, Open -Label Study of Vedolizumab (anti -


 antibody ) in Subjects with HIV Infection Undergoing 
Analytical Treatment Interruption  
 
Short Title:  Therapeutic Vedolizumab  
 
Clinical Phase:  1 
 
IND Sponsor:    OCRPRO  
 
Conducted by:   NIAID/LIR  
 
Principal Investigator:  Michael C. Sneller, MD  
 
Sample Size:  N= up to 20  
 
Accrual Ceiling:  40 
 
Study Population:   HIV-infected Adults (age 18 -65 years) on cART with 
suppressed viremia  
 
Accrual Period:   18 months  
 
Study Design:   An exploratory, open -Label, single arm study of 
vedolizumab  in subjects with HIV Infection undergoing 
analytical  treatment interruption   
 
Study Duration:   Start Date:  April 2016    
  End Date:  July 2018  
 
Study Agent :    Vedolizumab 300 mg  
  
Primary Objective:   To evaluate the safety and tolerability of vedolizumab in 
HIV-infected individuals prior to and following analytical  
treatment interruption  (ATI) . 
 
Protocol Version 5.0  
22-March -2017 
 
Page 9 of 53 
 Secondary Objective:  To evaluate the effect  of vedolizumab  administration  on 
plasma viral rebound in HIV -infected individuals following 
ATI 
 
 
Endpoints:   
1. The rate of occurrence of grade 2 or higher AEs, including SAEs, which are 
probably or  definitely related to vedolizumab . 
2. The n umber of subjects who experience rebound of plasma viremia  following 
ATI and meet criteria to restart cART  before week 48  
 
Protocol Version 5.0  
22-March -2017 
 
Page 10 of 53 
 Précis  
 
While combination antiretroviral therapy (cART) has improved the clinical outcome for 
HIV-infected individuals, persistence of viral reservoirs in the peripheral blood and 
lymphoid tissues remain s a hurdle to complete eradication of virus and cure of the 
infection . The concept that HIV preferentially infects discrete subsets of CD4+ T cells 
underscores the need to develop therapeutics that exploit specific cell -virus 
interactions. T cells expressing integrin 47 not only regulate migration into the gut -
associated lymphoid tissue (GALT), but also concomitantly bind HIV, placing them in a 
prime position to disseminate HIV throughout the tissue . Previously, it has been show n 
that the HIV envelope protein gp120 binds to 47 on CD4+ T cells in vitro , 47high 
CD4+ T cells are highly susceptible to productive HIV infection in vitro , and the 
administration of anti -47 monoclonal  antibody (mAb) prevents and/or delays 
transmission of SIV upon repeated challenges and preserves CD4+ T cells in rhesus 
macaques. Furthermore, it has been demonstrated that administration of anti -47 
mAb in SIV -infected rhesus macaques receiving cART sup presses plasma viremia for 
extended periods following discontinuation of cART, collectively suggesting that 
sustained virologic remission in the absence of cART may be achieved via direct 
targeting of 47 integrin. It is well established that the vast majority of HIV -infected 
individuals treated with  cART experience plasma viral rebound within weeks of  
cessation of therapy. Considering that current research on the treatment of HIV -infected 
individuals has been heavily focused on developing strategies aimed at achieving 
sustained virologic remission in the absence of cART, it is of great interest to 
investigate whether administration of anti-47 mAb can prevent plasma viral rebound 
and allow durable suppres sion of viral replication in HIV -infected individuals after 
discontinuation of cART. We propose to examine the effect of vedolizumab, an FDA -
approved anti-47 mAb for the treatment of ulcerative colitis and Crohn’s disease, on 
plasma viral rebound in HIV -infected individuals following analytical treatment 
interruption (ATI).  
Protocol Version 5.0  
22-March -2017 
 
Page 11 of 53 
 1 Background Information and Scientific Rationale  
1.1 Background Information  
Prolonged suppression of plasma viremia is now achievable in the majority of HIV -
infected individuals receivin g cART1. Complete eradication  of virus , however, has not 
been possible with cART alone due to the persistence of viral reservoirs  in a variety of 
tissues  2-5. Previous studies have demonstrated that  HIV persists in latently infected, 
CD4+ T cells in the peripheral blood of virtually all infected individuals receiving clinically 
effective cART 6-8. In a ddition, recent studies suggest that low levels of HIV replication 
may persist even in the absence of detectable viremia5,9,10. As plasma v iremia appears 
to rebound in nearly all HIV-infected individuals upon cessation of cART regardless of 
duration and timing of therapy11-13, alternative therapeutic strategies aimed at 
destroying or permanently suppressing persistently infected cells are need ed to 
potentially eradicate HIV 14. 
 
Despite the success of cART in suppressing plasma viremia and HIV replication, the 
burden of taking daily medication for life, long -term toxicity of cART regimens, and 
potential resistance to antiretroviral drugs, necessitates a continued search for effective 
alternatives for the control of HIV infection. Consequently, a major thrust of HIV 
research over the past several years has been to develop therapeutic strategies that 
target the persisten t HIV reservoir  and could induce a  sustained virologic remission in 
infected individuals in the absence of cART. To this end, numerous attempts have been 
made to purge the persistent HIV reservoir in infected individuals receiving cART . 
These include the u se of non -specific immune -activating agents, such as IL -2 15 and an 
anti-CD3 antibody 16, as well as  histone deacetylase inhibitors, such as valproic acid 
and vorinostat 17,18. However, these reagents neither prevented plasma viral rebound 
following cessation of cART nor decreased the size of the persistent viral reservoir in 
HIV-infected individuals . 
 
Other therapeutic strategies aimed at achieving eradication are under investigation. 
These include genetic manipulation of CD4+ T cells 19 and stem -cell transplantation 20. 
While  it appears that eradication of HIV was achieved in one individual who underwent 
multiple r ounds of chemotherapy and stem  cell transplantation 20, this a pproach is  
currently impractical and unlikely to be safely applied to a substantial proportion of the 
HIV-infected population.  
 
In recent years, research directed at the development of an effective HIV vaccine has 
provided insights into the nature of the immune response to HIV infection21,22. Antibody 
cloning technologies and B cell biology have led to the discovery of several highly 
potent and broadly neutralizing mAbs against HIV produced by B cells of some HIV -
infected individua ls 23-25. Several studies have demonstrated that certain broadly 
neutralizing HIV -specific mAbs can prevent acquisition of the virus, suppress viral 
replication, prevent plasma viral rebound following treatment interruption in infected 
animals 26-28, and block cell -to-cell transmission of laboratory -adapted HIV in vitro 29. 
However, durable  suppression of virus has yet to  be achieved via these modalities.  
 
As mechanisms for viral entry are discovered, alternative methods of viral suppression 
may emerge. Recent investigations have revealed a potential access point via 
Protocol Version 5.0 
22-March-2017  
 
Page 12 of 53 
 engagement of the cell surface integrin 47 by HIV gp120 on CD4+ T cells30,31. The 
47 integrin is expressed on the surfac e of a discrete subset of  T-lymphocytes that 
facilitates preferential  migration  into the gastrointestinal tract. Integrin 47 mediates 
homing of T lymphocy tes to the gut by binding to  mucosal addressin cell adhesion 
molecule -1 (MAdCAM -1), an adhesion molecule preferentially expressed on venules in 
gut associated lymphoid tissue  (GALT) . 
 
In addition to preferentially migrating to GALT , α4β7high CD4+ T are highly susceptible to 
productive HIV infection in vitro .  Furthermore, it has been shown that  α4β7  integrin on 
CD4+ T cells binds HIV gp120  leading to rapid activation of LFA -1, the integrin involved 
in the establishment of virologi c synapses 30,31. Thus, α4β7high CD4+ T cells are  in a 
prime p osition to disseminate HIV between GALT and the periphery. Based on these 
observations, the efficacy of  47-mAb therapy in preventing transmission was 
evaluated in a nonhuman primate model 32. Initial results revealed that  administration  
anti-47 mAb  prior to and during acute infection protected rhesus macaques from 
transmission after repeated low -dose intravaginal challenges with SIVmac251 . In the 
treated animals that became infected, GALT was protected from infection and CD4+ T 
cells were maintained  in both the periphery and GALT32. These results suggest that 
antibodies directed against 47 might have  potential as an immune -based therapy for 
HIV.  
 Description of the Study Agent   
Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin and blocks the interaction of α4β7 integrin with MAdCAM -1, which in turn  
inhibits the migration of T -lymphocytes across the endothelium into GALT . Vedolizumab 
does not bind to or inhibit function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 integrins with vascular cell adhesion molecule -1 
(VCAM -1). 
 
Consist ent with its specificity for α4β7 , IV administration of vedolizumab  did not elevate 
neutrophils, basophils, eosinophils, B helper and cytotoxic T  lymphocytes, total memory 
T helper lymphocytes, monocytes or NK cells in the peripheral blood  of healthy subje cts 
or subjects with  UC or  CD (Vedolizumab Investigators Brochure, Dec. 2015) . 
Vedolizumab did not affect immune surveillance and inflammation of the central 
nervous sy stem ( CNS ) in experimental autoimmune encephalitis  in nonhuman  
primates, a model of multiple sclerosis
33. Consistent with these results, vedolizumab IV 
did not alter the ratio of CD4+/CD8+ T cells or the number of T cells in the CSF of 
healthy subjects34. Vedolizumab IV did not inhibit the  adaptive immune response to 
intramuscular antigen challenge with  hepatitis B vaccine in healthy subjects, but did 
inhibit an adaptive immune response to oral  antigen challenge with killed cholera toxin 
vaccine35. These results support t he conclusion that, unlike natalizumab (a duel α4β7  
and α 4β1 antagonist), vedolizumab selectively inhibits  migration of T lymphocytes to 
the gut and does not inhibit central nervous system or systemic immune response s in 
humans.  
 
Clinical Pharmacology  
The single and multiple dose  pharmacokinetics  (PK) of vedolizumab IV have been 
investigated  in completed studies in  healthy subjects and in subjects with moderately to 
severely active UC or CD . Similar PK was observed in healthy subjects, as well as in 
subjects with UC or CD. Vedolizumab  clearance  depends on both linear and nonlinear 
Protocol Version 5.0 
22-March-2017  
 
Page 13 of 53 
 pathways; with linear PK observed at serum  concentrations >1 μg/mL to 10 μg/mL. 
Population PK analyses indicate that the linear clearance  was approximately 0.157 
L/day, the serum terminal  elimination half -life was approximately 25 days at the 300 mg 
dosage, and the  volume of distribution at steady state  was approximately 5 L. 
Vedolizumab was not detected in the CSF of 14 healthy subjects at  5 weeks after a 
single intravenous ( IV) administration of 450 mg vedolizumab (1.5 times the 
recommended  dosage) . 
 
Clinical Pharmacodynamics  
 
Two pharmacodynamic  markers (Act- 1 and MAdCAM -1-Fc) were independently 
evaluated to assess the  presence of 47 integrin binding sites on cell surfaces and to 
determine the number of free 47 receptor sites by vedolizumab. Vedolizumab 
inhibition of Act -1 and  MAdCAM -1-Fc binding to the 47 receptor indicated the extent 
of 47 receptor saturation by  vedolizumab36. 
Dose -dependent duration of 47 receptor saturation was consistently observed 
following both  single and multiple dosing in phase 1 studies. Rapid and near complete 
47 receptor saturation  was achieved following dosing and the time to loss of 47 
receptor saturation was dose  dependent.  The serum concentrations of vedolizumab 
following 300 mg dosing every 4 -8 weeks  are expected to maintain >90% α4
 7 
receptor binding saturation over the dosing interval in >90% of  subjects36,37.  
 Summary of Pre- Clinical Nonhuman Primate Studies  
 
Based on the  results  of the nonhuman primate studies demonstrating efficacy of anti -
47 mAb in preventing  SIV infection  (see Section 1.1) , a follow -up study  was designed 
to investigate  the potential therapeutic effects of anti -47 mAb  in SIV infected 
macaques  (A. Ansari unpublished data) . The anti-47 mAb used in these studies 
contains the same antigen binding region as vedolizumab fused to a rhesus IgG1 Fc  
region38.  In this study, 10 rhesus macaques were infected with SIVmac239 
intravenously. When the animals reached steady state viremia, they were initiated on 
cART. Once viral levels were suppressed  on cART, the monkeys were divided into two 
groups ; the control group received  50 mg/kg  IV of normal rhesus IgG, while group 2 
received 50 mg/kg IV of  anti-47 mAb. Infusions were  administered every three weeks 
for a to tal of 8 infusions. After four infusions, cART  was stopped  in order to d etermine 
the effect of anti -47 mAb  alone  on the expected rebound of plasma viremia   
(Figure 1.1.2 -1).  
 
As expected, all five animals in the IgG control group experienced a rebound of viremia 
within 2 weeks of stopping cART. In contrast, 4/5 monkeys in the anti -47 mAb group 
exhibited intermittent or continued suppression of plasma viremia  (Figure 1.1.2 -1). In 
these animals, suppression of plasma viremia persisted, in the absence of cART 
through week 45  (12 weeks after the last anti -47 mAb).  The single animal in the  anti-
47 mAb group (RNo13) that exhibited rebound viremia was shown to have 
developed antibodies against the 47 mAb that became detectable after the third 
infusion .  
 
Pr ot o c ol V er si o n 5. 0 
2 2 - M ar c h- 2 0 1 7  
 
P a g e 1 4  of 5 3  
 A s e c o n d st u d y w a s d e si g n e d i n t h e s a m e m a n n er wit h t h e a d diti o n of 8 a ni m al s, 2 of 
w hi c h w er e a d d e d t o t h e I g G c o ntr ol gr o u p a n d 6 of w hi c h r e c ei v e d a nti -47 m A b.  
 
 
Fi g ur e 1. 1. 2 - 1 . N o n h u m a n Pri m at e Tri al D e si g n  
 
 
 
B ot h  of t h e c o ntr ol m o n k e y s e x p eri e n c e d vir al r e b o u n d  wit hi n 2 w e e k s of st o p pi n g 
c A R T. T w o  of  t h e m o n k e y s i n t h e tr e at m e nt gr o u p  d e v el o p e d a nti b o di e s  a g ai n st t h e 
47 m A b  a n d  e x hi bit e d r e b o u n d vir e mi a si mil ar t o t h e c o ntr ol a ni m al s  ( Fi g ur e 1. 1. 2 - 3) . 
Of t h e r e m ai ni n g 5 a ni m al s i n t h e tr e at m e nt gr o u p, 2 s h o w e d s u st ai n e d s u p pr e s si o n of 
pl a s m a vir e mi a o ut t o st u d y w e e k 4 0 ( 8 w e e k s aft er t h e l a st a nti -47 m A b i nf u si o n). 
Th e ot h er 3  a ni m al s s h o w e d i nt er mitt e nt l e v el s of pl a s m a vir e mi a.   
 
 
 
 
 
 
Fi g ur e 1. 1. 2 - 2. SI V Pl a s m a Vir e mi a i n 47 m A b Tr e at e d A ni m al s -Tri al 1  SI V m a c 2 3 9 
I nf e ct i o n 
( 2 0 0 T CI D 2 0 0 )
0 2 5 1 2 9 1 5 5 1 8 2 2 c A R T 
i niti at e d c A R T 
t e r mi n at e d 
3 6 4 0 5 0 
a4 ß 7 o r 
I g G 
a d mi ni st r a ti o n A R T 
A n ti -a4 ß 7 
a n ti b o d y W e e k 
Protocol Version 5.0  
22-March -2017 
 
Page 15 of 53 
  
 
 
 
Figure 1.1.2 -3. SIV Plasma Viremia in 47 mAb Treated Animals -Trial 2  
 
 

Protocol Version 5.0 
22-March-2017  
 
Page 16 of 53 
 
 Summary of Relevant Clinical Studies  
 
Vedolizumab (ENTYVIO) is approved by the FDA for treatment of adult patients with 
moderately to severely active ulcerative colitis  (UC) or Crohn’s disease (CD) who have 
had an inadequate response to, or were intolerant to a tumor necrosis factor (TNF) 
blocker or immunomodulator; or had an inadequate response with, were intolerant to, or  
demonstrated dependence on corticosteroids. The FDA approval was based largely on 
the results of 2  two integrated  randomized controlled studies  in UC39 and 2 integrated 
randomized controlled studies in CD40.  In these studies, the dose of vedolizumab was 
300 mg IV.  
 
Ulcerative Colitis  (UC)  
In a randomized, multicenter trial, 374 patients with active UC were assigned to 
vedolizumab or placebo for the induction of remission39. A significantly greater 
proportion of vedolizumab -treated patients achieved clinical response, remission, and 
mucosal healing at six weeks compared with  placebo. In a trial of vedolizumab for the 
maintenance of remission, 373 patients with a clinical response to vedolizumab at six 
weeks, in either the induction trial or following open label treatment, were assigned to 
continue to receive vedolizumab every eight weeks, four weeks, or switch to placebo for 
up to 52 weeks. At week 52, remission rates were significantly higher in patients who received vedolizumab compared with placebo.  
 
Crohn’s Disease  (CD)  
A randomized trial enrolling  368 patients with moderately to severely active CD who 
had failed at least one conventional therapy were assigned to vedolizumab or placebo 
for induction therapy40. At week 6, rates of clinical remission were significantly higher in 
patients treated with vedolizumab as compared with placebo (14 versus 7 percent). 
This same trial also looked at the ability of vedolizumab to maintain remission. A total 
461 patients who had had a prior clinical response to vedolizumab were randomly 
assigned to receive placebo or vedolizumab every 8 or 4 weeks until week 52. Subjects  
randomized to vedolizumab for maintenance therapy were more likely to be in 
remission  at week 52.  
 
Summar y of Adverse Events in Inflammatory Bowel disease Trials  
The data described  in Table 1.1.3 -1 reflect exposure to vedolizumab in patients 
participating in the  four Phase 3 trials39,40. In these trials, 1,434 patients received 
vedolizumab  300 mg for up to 52 weeks, and 297 patients  received placebo for up to 52 
weeks. Of these, 769 patients had UC and 962  patients had CD . Patients were exposed 
for a mean duration of 259 days ( UC) and 247 days ( CD). In these studies, concomitant 
treatment with stable doses of prednisone and/or  immunosuppressive agents were 
allowed. Adverse reactions were reported in 52% of patients treated with vedolizumab  
and 45% of patients  treated with placebo. Serious adverse reactions were reported  in 
7% of patients treated with vedolizumab  compared to 4% o f patients treated with 
placebo.   
 The most common adverse reactions  were nasopharyngitis, headache, arthralgia, 
nausea, pyrexia, upper respiratory  tract in fection, fatigue, cough, bronchitis, influenza, 
back pain, rash, pruritus, sinusitis,  oropharyngeal pain and pain in extremities (Table 
1.1.3 -1). 
  
Protocol Version 5.0  
22-March -2017 
 
Page 17 of 53 
  
 
 
 
Table 1.1.3 -1. Adverse Reactions in ≥ 3% of Vedolizumab -treated Patients and 
≥ 1% Higher than in Placebo  
            Vedolizumab *  Placebo ** 
 
* Patients who received v edolizumab for up to 52 weeks  
** Patients who received placebo for up to 52 weeks  
 
 
Laboratory Abnormalities  
No clinically important treatment group differences in patients with markedly abnormal 
values in  laboratory tests (hematology, chemistry , or coagulation)  were observed in any 
of the phase 3 studies.  
 
Infusion -Related Reactions  
Serious infusion -related reactions following vedolizumab administration have been 
reported in clinical trials. In the UC and CD phase III trials described above, a single 
case of anaphylaxis (1/1434 subjects -0.07%) was reported in a patient with CD 
following the second infusion of vedolizumab. In these same trials, other infusion -
related reactions were reported in 4% of patients treated with vedolizumab and 3% of 
patients treated with placebo. The most common reactions w ere nausea, headache, 
pruritus, dizzine ss, fatigue, pyrexia, urticaria , and vomiting. These reactions generally 
occurred during the infusion, and reso lved either with no treatment or  following 
administration of antihistamine and/or hydrocortisone. Less tha n 1% of patients treated 
with vedolizumab developed infusion reactions assessed by the investigator as being 
severe.  

Protocol Version 5.0  
22-March -2017 
 
Page 18 of 53 
  
Infections  
In the Phase III UC and CD Trials, the rate of infections was 0.85 per patient -year in  the 
patients treated with vedolizumab  and 0.7 per patient -year in the patients treated with 
placebo. The infections consisted primarily of nasopharyngitis,  upper respiratory tract 
infection, sinusitis, and urinary tract infection. Two percent of patients  discontinued 
vedolizumab  due to infectio ns. 
 
The rate of serious infections was 0.07 per patient -year in patients treated with 
vedolizumab  and 0.06 per patient -year in patients treated with  placebo. Serious 
infections were more common in CD patients than UC patients, and anal abscesses 
were the most frequently reported serious infection in CD  patients. Over 48 months, 
there was no increase in the rate of  serious infections.  Sepsis was reported in 4 of 1434 
(0.3%) of patients treated with vedolizumab compared with 2 of 297 (0.7%). patients 
treated  with placebo.  
 
In controlled - and open -label long -term extension trials in adults treated with 
vedolizumab , serious infections have been reported, including anal abscess, sepsis 
(some fatal),  tuberculosis, salmonella sepsis, Listeria meningitis, giardiasi s, and 
cytomegalovirus  colitis.  No cases of PML were reported.  
 
Liver Injury  
In the UC and CD phase III trials there were reports of elevations in hepatic 
transaminases and/or bilirubin. Three patients in the UC and CD trials reported SAE 
related to hepatitis. Based on case report information, it is unclear  if these SAE were 
related to concomitant medication s (e.g. 6 -mercaptopurine)  or autoimmune processes  
(sclerosing cholangitis) . All patients recovered. In controlled trials, ALT/AST elevations  
≥3 X upper limit of normal  were seen i n <2% of patients in both the placebo and  
vedolizumab groups .  
 
Immunogenicity  
In the completed 52 -week controlled studies in subjects with UC or CD, vedolizumab IV 
showed  an immunogenicity rate of 4%; 56 of 1434 subjects who received continuous 
treatment with  vedolizumab IV tested positive for anti -vedolizumab antibodies at any 
time during treatment . Nine of these 56 subjects  were persistently positive (positive at 
≥2 study visits) and 33 subjects developed  neutralizing antibodies. As with all 
therapeutic proteins, there is potential for immunogenicity. In UC Trials I and II and CD 
Trials I and III, in patients who received vedolizumab , the frequency of antibodies 
detec ted in patients was 13% at 24 weeks after the last dose of study drug (greater 
than five half -lives after last dose) . 
 
Overall, there was no apparent correlation of anti-vedolizumab antibodies , clinical 
response , or treatment related AE . However, the numbe r of subjects who developed 
antibodies  was too limited to make a definitive  assessment.  
 
Post  Marketing Experience  
Based on drug shipment data as of 19 May 2015, the post marketing  patient exposure 
to vedolizumab IV globally is estimated to be app roximatel y 11,943 patient -years.  
The post  marketing safety profile of vedolizumab IV is consistent with what was seen in 
the clinical studies  and n o new safety signals have been identified  (vedolizumab 
Investigators Brochure,  Dec. 2015) . 
Protocol Version 5.0  
22-March -2017 
 
Page 19 of 53 
 1.2 Rationale  
Vedolizumab as a Potential Treatment for HIV Infe ction  
The results in the  nonhuman primate SIV study described in Section 1.1.2, suggest that 
blockade of 47 with vedolizumab in virologically suppressed patients with HIV 
infection has the potential to ind uce sustained suppression of viremia after 
discontinuation of cART  and anti -47 mAb administration .  The purpose of this study 
is to test this hypothesis and evaluate the safety of vedolizumab in an exploratory open 
label study.  
 
Use of Analytical Treatment Interruption  (ATI)  
Various assays measuring HIV -specific immune responses  and the  frequency of CD4+ 
T cells carrying infectious HIV  have been used to assess efficacy of immune -based 
therapies . To date, none of the assays are clinically  validated to predict actual antiviral 
efficacy. Thus, ATI has been used to evaluate the anti-viral efficacy  of immune -based 
therapies  by testing the ability of these interventions to blunt or prevent the viral 
rebound that  occurs following  interruption  of cART . The use of ATI in the design of this 
study  is the only way to determine if administration of v edolizumab  results in clinically 
significant antiviral activity , as evidenced by a blunted or absent plasma viral rebound 
following ATI.  
2 Study Objectives  
2.1 Primary Objective  
• To evaluate the safety and tolerability of vedolizumab in HIV -
infected individuals prior to and following analytical  treatment 
interruption (ATI)  
 
2.2 Secondary Objective  
• To evaluate the effect of vedolizumab administration on plasma 
viral rebound in HIV -infected individuals following ATI  
2.3 Exploratory Objectives  
• To determine the effect of vedolizumab on the size of persistent 
HIV reservoirs  
 
• To examine the impact of vedolizumab on continuing /residual 
HIV replication prior to discontinuation of cART  
3 Study Design  
3.1 Description of the Study Design  
The proposed trial will be a single arm, open label stud y to examine the effect of 
vedolizumab  on plas ma viral rebound in HIV -infected individuals following an 
analytical treatment interruption (ATI). Fifteen  HIV-infected individuals with 
suppressed viremia on  cART will be studied. All study participants will receive  a 
total of 9  IV infusions of vedolizuma b 300 mg  (Figure 1.1.3 -1).   
Protocol Version 5.0 
22-March-2017  
 
Page 20 of 53 
  
 
 
Figure 1.1.3 -1. Study  Design  
 
 
 
At study week 22 , all subjects will discontinue cART and enter the ATI phase of the 
study . Individuals taking non -nucleoside reverse transcriptase inhibitors (NNRTIs) 
will switch to a protease inhibitor or an integrase inhibitor -based regimen  at least  2 
weeks prior to week 22  to ensure that the washout period of antiretroviral agents is 
roughly  equal.  HIV plasma viral levels and CD4+ T cell counts will be monitored 
every 2 weeks during the ATI phase. If a subject  meet s any of the following criteria 
between study weeks 22 -30, they will  discontinue vedolizumab infusions,  re-start 
ART, and enter the follow -up phase. Subjects who meet any of the criteria for 
restarting cART after week 30, will restart cART and enter the follow -up phase.  
 
 
Criteria to Restart cART  
 
• A confirmed >30% decline in baseline CD4+ T cell count or an absolute 
CD4+ T cell count <350 cells/mm3 in the setting of detectable (>40 
copies/ml) HIV viremia . 
• A sustained (>4 weeks) HIV RNA level of >1,000 copies/mL  
• Any HIV -related symptoms (e.g. acute retroviral syndrome, opportunistic 
infection)  or pregnancy  
3.2 Study Endpoints 
 Primary Endpoint 
The rate of occurrence of grade 2 or higher AEs, including SAEs, 
which , are probably or  definitely related  (as defined in Section 11.3.2)  
to vedolizumab.  
 Secondary Endpoints 
Number of subjects who experience rebound of plasma viremia  
following ATI and meet criteria to restart cART  before week 48 . 
  
ART Phase (22 weeks)  
Infusions of  
vedolizumab  
0 
 48 
 22 
 26 
 6 
ATI-Follow -up Phase  
  
  
2 
 10 
14 
  
   
   
   
   
   
30 
  
Cessation  
of ART  
18 
  
Protocol Version 5.0  
22-March -2017 
 
Page 21 of 53 
  
4 Study Population  
4.1 Recruitment Plan  
Subjects will be recruited from existing cohorts of individuals participating in 
NIAID protocols 09 -I-0030 and 02 -I-0202 who meet the Inclusion/Exclusion 
Criteria. Additional local and regional  recruitment will be done using direct mailing 
to infectious di sease physicians, internet ad campaigns, social media outlets, 
print ads, and from local clinics via the N IAID patient recruitment contract with 
Matthews Media Group.  
4.2 Subject Inclusion Criteria  
 
1. Age, 18 -65 years  
2. Documented HIV-1 infection and clinically s table  
3. In general good health, with an identified primary health care provider 
for medical management of HIV infection and willing to maintain a 
relationship with a primary health care provider for medical 
management of HIV infection while participating in the study  
4. CD4+ T cell count >450 cells/mm3 at screening  
5. Documentation of continuous cART treatment with suppression  of 
plasma viral level below the limit of detection  for ≥2 years. Subjects 
with “blips” (i.e., detectable viral levels on  cART) prior to screening 
may be included provided they satisfy the following criteria:  
a. The “blips ” are <400 copies/mL, and  
b. Succeeding viral levels return to levels below the limit of 
detecti on on subsequent testing  
6. Willingness to undergo ATI  
7. Laboratory values within pre -defined limits at screening:  
• Absolute neutrophil count >1,000/mm3 
• Hemoglobin  (Hgb)  levels >10.0 g/dL for men and >9.0 g/dL for 
women  
• Platelet count >100,000/mm3 
• Prothrombin t ime (PT) and partial thromboplastin time (PTT) <1.5 
upper limit of normal (ULN)  
• Estimated glomerular filtration rate (eGFR) of ≥50 mL/min as 
determined by the NIH Clinical Center laboratory  
• Aspartate aminotransferase ( AST) and alanine aminotransferase  
(ALT) levels of < 1.1 x ULN . Total bilirubin <1. 1 x ULN (unless 
subject is taking atazanavir or has Gilbert’s Syndrome)  
8. Willingness to have samples stored for future research  
 
Protocol Version 5.0  
22-March -2017 
 
Page 22 of 53 
 Participation of Women:   
Contraception: The effects of vedolizumab  on the developing human fetus 
are unknown.  For this reason, men and women of childbearing potential 
must agree to use adequate contraception (hormonal or barrier method of 
birth control; abstinence) prior to study entry and for the duration of study 
participation.   
4.3 Subject Exclusion Criteria  
 
1. Chronic hepatitis B, as evidenced by a positive test for hepatitis B surface 
antigen (HBsAg), or chronic hepatitis C virus (HCV) infection, as evidenced 
by a positive test for HCV RNA. Subj ects with a positive test for HCV 
antibody and a negative test for HCV RNA are  eligible . 
2. Documented nadir CD4+ T cell count <200  cells /mm3 
3. Documented multiclass antiretroviral drug resist ance that, in the judgment  of 
the investigator , would pose a risk of virologic failure should additional 
mutations develop during the study 
4. HIV immunotherapy or vaccine(s) received within 1 year prior to screening  
5. Any licensed or experimental non -HIV vaccination (e.g., hepatitis B, 
influenza, pneumococc al polysaccharide) received wit hin 2 weeks prior to 
study enrollmen t  
6. Receipt  of other investigational study agent within 28 days of enrollment  
7. Any active malignancy that may require systemic chemotherapy or radiation 
therap y 
8. Systemic immunosuppressive medications received within 3  months prior to 
enrollment . The following are not  excluded: [1] corticosteroid nasal spray or 
inhaler; [2] topical corticosteroids for mild, uncomplicated dermatitis; and [3] 
oral/parenteral corticos teroids administered for non -chronic conditions not 
expected to recur (length of therapy ≤10 days, with completion in ≥30 days 
prior to enrollment ) 
9. History or other clinical evidence of:  
• Significant or unstable cardiac disease (e.g., angina, congestive heart 
failure, recent myocardial infarction)  
• Severe illness, chronic liver disease, malignancy, immunodeficiency 
other t han HIV,  active systemic infection other than HIV,  or any other 
condition  that, in the opinion of the investigator, would mak e the subject 
unsuitable for the study  
• Active or latent tuberculosis, regardless of treatment history  
10. Neurologic  or neuropsychiatric disorder , the symptoms of which  mimic PML 
and could  interfere with the assessment of safety ( e.g. history of encephalitis  
with motor sequela , stroke with sequela, severe majo r depressive disorder, 
severe bipolar disorder, seizure disorder ) 
Protocol Version 5.0 
22-March-2017  
 
Page 23 of 53 
 11. Active drug or alcohol abuse or any other pattern of behavior  that, in the 
opinion of the investigator, would interfere with adherence to study 
requirement s 
12. Pregnancy or breast -feeding  
 
Routine Vaccination Asses sment : During screening, subjects ’ vaccination history will 
be assessed. If subjects are not up to date on routine vaccinations (as recommended in  
DHHS Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV -
Infected Adults and Adolescents ), they will be offered vaccination prior to initiating 
treatment with vedolizumab .  
 
Co-enrollment Guidelines: Co-enrollment in other trials is restricted, other than 
enrollment on observational studies. Study staff should be notified of co -enrollment as it 
will require the approval of the Principal  Investigator . 
4.4 Justification for Exclusion of Women, Min orities, and Children 
(Special Populations)  
 Exclusion of Children:    
 
Because there are insufficient data regarding dosing or adverse events available in 
adults to judge the potential risk in children, children are excluded from this study.  
 
5 Study Agent/Interventions  
5.1 Disposition and Dispensation  
Study agent will be distributed via the NIH Central Pharmacy according to standard 
pharmacy procedures.  
 Formulation, Packaging and Labeling  
Vedolizumab  is supplied in sterile 20 mL single -use glass vials,  containing 300 mg of 
vedolizumab as a white to off -white cake. Refrigerate each unopened 300mg single 
dose vial in an individual carton at 2° to 8
 C (36º to 46ºF) . Retain in original package to 
protect from light.  
5.2 Study Agent Storage and Stability  
The si te pharmacist must promptly report any storage temperature excursions outside 
of the normal allowance for the storage device to the PI and the IND Sponsor. The 
product must be quarantined in a separate area.  The IND Sponsor’s authorized 
representative will notify the site pharmacist if continued clinical use of the product is 
acceptable.  
5.3 Preparation, Administration, and Dosage of Study Agent 
Reconstitution Instructions  
Protocol Version 5.0  
22-March -2017 
 
Page 24 of 53 
 Reconstitute vedolizumab  at room temperature. Vedolizumab  will be reconstituted and 
prepared  by the NIH Pharmacy using aseptic technique by the following procedure:  
 
1. Remove the flip -off cap from the single -dose vial and wipe with alcohol swab.  
Reconstitute vedolizumab  vial containing lyophilized powder with 4.8 mL  of sterile water 
for injection, using a syringe with a 21 to 25 gauge needle.  
 
2. Insert the syringe needle into the vial through the center of the stopper and direct the  
stream of sterile water for injection to the glass wall of the vial to avoid excessi ve 
foaming.  
 
3. Gently swirl the vial for at least 15 seconds to dissolve the lyophilized powder. Do not   
vigorously shake or invert.  
 
4. Allow the solution to sit for up to 20 minutes at room temperature to allow for  
reconstitution and for any foam to set tle; the vial can be swirled and inspected for  
dissolution during this time. If not fully dissolved after 20 minutes, allow another  
10 minutes for dissolution. Do not use the vial if the drug product is not dissolved within  
30 minutes.  
 
5. Vis ually inspect the reconstituted vedolizumab solution for particulate matter and  
discoloration prior to administration. Solution should be clear or opalescent, colorless to  
light brownish yellow , and free of visible particulates. Do not administer reconstit uted 
solution showing uncharacteristic color or containing particulates.  
 
6. Prior to withdrawing the reconstituted vedolizumab solution from the vial, gently invert 
vial 3 times.  
 
7. Withdraw 5 mL (300 mg) of reconstituted vedolizumab solution using a syr inge using  
a 21 to  25 gauge needle. Discard any remaining portion of the reconstituted solution in 
the vial.  
 
Dilution Instructions  
Add the 5 mL (300 mg) of reconstituted vedolizumab solution to 250 mL of sterile 0.9% 
sodium  chloride and gently mix the inf usion bag. Do not add other medicinal products to 
the prepared  infusion solution or intravenous infusion set. Once reconstituted and 
diluted, use the infusion  solution as soon as possible.  
 
Storage  
If necessary, the infusion solution may be stored for up t o four hours at 2° to 8°C (36º to 
46ºF).  Do not freeze. Discard any unused portion of the infusion solution.  
 
The dose of vedolizumab  for this study is 300 mg  in 250 mL normal saline.   
  
The investigational study product solution will be administered  by IV infusion  over at 
least 3 0 minutes using a volumetric pump. The total time needed to administer the dose 
may be longer than 3 0 minutes based on factors such as subject tolerance.  After the 
infusion is complete, the IV line will be flushed  with 30 ml of normal saline.  
 
Protocol Version 5.0 
22-March-2017  
 
Page 25 of 53 
 For women of childbearing potential, study agent administration may not proceed 
unless a negative pregnancy test has been obtained within the previous 24 hours. Prior 
to each administration, temperature, blood pressure, heart  rate (pulse) and weight will 
be recorded . Vital signs (temperature, blood pressure,  heart rate) will be measured 15  
minutes into the infusion and at the end of the infusion. Following  completion of the first 
infusion, the subject will be monitored  for 2 hours  before leaving  the clinic. For 
subsequent infusions, the subject will be monitored for 1 hour after completion of the infusion.  
 Dose Adjustments and Modifications  
Should m ild-moderate infusion -related symptoms  (Grade I -II) develop, they will be 
managed by temporarily stopping the infusion  until symptoms have resolved. For 
symptoms such as fever, myalgia,  or urticaria,  symptomatic treatment with  standard 
doses of acetaminophen or antihistamines  may be given. Once symptoms have 
resolved, the infusion will be restarted  at half the initial rate. If symptoms recur  following  
a reduced infusion rate and symptomatic treatment, the infusion will again be stopped 
until symptoms resolved and restarted at a lower ra te. If the infusio n cannot be 
completed within a 3 -hour time frame because of recurrent symptoms, the infusion will 
be discontinued for that visit.  
 Duration of Therapy 
The planned total duration of  vedolizumab  therapy is 30  weeks . 
5.4 Concomitant Medications and Procedures  
All concomitant prescription medications taken during study participation will be 
recorded in CRIMSON. For this protocol, a prescription medication is defined as a 
medication that can be prescribed only by a properly authorized/licensed clinician.  
Medications to be reported in CRIMSON  are concomitant prescription medications, 
over-the-counter medications and non -prescription medications taken at the time of 
adverse events (all grades).  
5.5 Prohibited Medications and Procedures  
Treat ment with immunosuppressive medications  during the study is prohibited. 
Prohibited immunosuppressive medications do not  include  [1] corticosteroid nasal 
spray  or inhaler; [2] topical corticosteroids for mild, uncomplicated dermatitis; or [3] 
oral/parenteral corticosteroids given for non -chronic conditions not expected to 
recur. 
6 Study Schedule  
For all the study visits, unless otherwise specified, subjects will come to the NIH 
Clinical Center to undergo the procedures. Unless otherwise specified, the visit 
window for the post -entry study visits is ± 5 days.  
6.1 Screening  
Protocol Version 5.0  
22-March -2017 
 
Page 26 of 53 
 Screening may occur over the course of several contacts/visits. All inclusion and 
exclusion criteria must be assessed within 8 weeks before enrollment, unless 
otherwise specified in the e ligibility criteria.  
After signing informed consent, subjects will undergo the following procedures:  
• Medical history and a physical examination, including weight, vital signs, and a 
symptom -directed evaluation based on symptoms or complaints reported by 
each participant.  
• Assessment of concomitant medications.  
• Blood collection for:  
o Hepatitis B Surface Antibody, HBsAg , Anti -HAV,  and Hepatitis C 
antibody serology  
o QuantiFERON® TB test  
o Complete blood count (CBC) with differential, PT, activated PTT  
o Chemistry panel to include: ALT, AST, al kaline phosphatase, creatinine , 
total and direct bilirubin, and serum albumin levels  
o Flow cytometry pa nel (includes CD4+ T cell count)  
o Plasma HIV and HCV viral RNA levels  
o Serum and plasma for storage  
• Urinalysis  
• Serum  or urine pregnancy test (for women of child -bearing potential)  
• Electrocardiogram (ECG)  
6.2 Enrollment/Baseline  
The enrollment visit may take place over 2 visits  to accommodate  the baseline 
pretreatment apheresis procedure. The first dose of vedolizumab  will be 
administered at this visit, and enrollment is defined as the day  and time  of receipt of 
the first dose of vedolizumab .  
Subjects will undergo the following proc edures (pr ior to the first dose of study drug ): 
• Medical history and a targeted physical examination, including weight, vital 
signs, and a symptom -directed evaluation based on symptoms or complaints 
reported by each participant  
• PML checklist (Appendix C)  
• Baseline n eurologic evaluation  by a neurologist  –screen  for signs and symptoms 
of PML  
• Assessment of concomitant medications  
• HIV transmission risk behavior assessment and counseling  
• Leukapheresis for research studies  
• Blood collection for:  
Protocol Version 5.0  
22-March -2017 
 
Page 27 of 53 
 o Flow cytometry panel (includes CD4+ T cell count)  
o Plasma HIV viral RNA level  
o HLA typing  (if not already on file)  
o Storage of plasma, serum and  peripheral blood mononuclear cells 
(PBMCs ).  Optional collection of PAXgene ® Blood RNA Tube  for 
storage.  
o CBC with differential  
o Chemistry panels, to include: ALT, AST, alkal ine phosphatase, 
creatinine , total and direct bilirubin, and serum albumin levels  
• Serum or urine pregnancy test (for women of child -bearing potential -obtained  
within 24 hours prior to infusion)  
6.3 Study Phase  (Figure 1.1.2 -1) 
 
Vedolizumab  will be administered on study day 0. Subsequent infusions of 
vedolizumab  (300 mg)  will be  given  at weeks 2, 6, 10, 14, 18 , 22, 26, and 30 ; for a 
total of 9 infusions . After the final infusion at week 30, all subjects will continue to 
be seen every 4 weeks until they restart cART. At infusi on visi ts and the monthly 
visits following week 30 , the following will be performed : 
• Medical history and a targeted physical examination, including weight, vital 
signs, and a symptom -directed  evaluation  
• Assessment of concomitant medications  
• Assessment of any new or unresolved AEs/intercurrent illnesses  
• PML checklist  (done prior to infusion  at infusion visits only ) 
• Neurologic examination - screen  for signs and symptoms of PML . Any subjects 
that develop signs or symptoms suggestive of PML will be evaluated by  a 
neurologist . No further vedolizumab doses will b e administered until 
appropriate workup (e.g. MRI) has been done to exclude a diagnosis of PML.  
• Blood collection : 
o CBC with differential.  
o Chemistry panels, to include: ALT, AST, alkali ne phosphatase, 
creatinine,  total and direct bilirubin, and serum albumi n levels.  
o Flow cytometry panel (includes CD4+ T cell count).  
o Plasma HIV viral RNA level  
• Serum or urine pregnancy test (for women of child -bearing potential) ; results 
must be reviewed prior to infusion    
• Storage of plasma, PBMCs, and s erum.  Optional collection of plasma , serum , 
and PAXgene ® Blood RNA Tube  for storage on day 3 (+/- 2 days) and week 1 
visits  (+/- 3 days).   Optional collection of PAXgene ® Blood RNA Tube  for 
storage on week 2 and week 6 visits.   
Protocol Version 5.0  
22-March -2017 
 
Page 28 of 53 
 • Leukapheresis for research  studies will be done within 14 days after  the study 
week 10  and 22  visits (prior to beginning ATI)  
• HIV transmission risk behavior assessment and counseling  
 
Analytical Treatment Interruption  
Following the  study week 22  visit, all su bjects will discontinue cART .  During the ATI , 
additional CD4+ T cell  count , storage of plasma,  and plasma HIV RNA levels will be  
obtained such that subjects will have these parameters  monitored every 2 weeks  during 
the ATI . Genotypic analysis for drug resistance mutations will be performed on all 
plasma samples with HIV viral levels >1,000 copies/ml. For select subjects residing 
outside the local (Bethesda, MD) area, blood samples for CD4+ T cell counts , and HIV 
viral levels , may be collected at their local clinics or Quest Diagnostics and sent to the 
NIH Clinical Center for testing .  Samples collected at clinics or at Quest may be labeled 
with a coded identifier, gender, and date of birth, as required by the local facility.  
 
If a subject develops one or more criteria for ending ATI  (see section 3.1) he/she  will be 
asked to return for assessment and confirmation of the laboratory/cli nical abnormality. If 
the criteria for ending ATI are met,  no further vedolizumab  infusions will be given , and  
the subject will  be instructed to  restart cART . He/she will  then undergo the schedule of 
procedures described  in Section 6.4.   At week 48, any subject  who has not met criteria 
to end the ATI but has  detectable  viremia (>40 copies/ml) will be instructed to restart 
cART. All subjects will  be followed for 6 months after  restarting cART.  If a subject does 
not have detectable  (>40 co pies/ml) viremia at week 48 , they may elect to remain off 
cART  and will be followed  until viremia becomes detectable.  For such subjects, 
laboratory studies will be continued per the schedule outlined in Section 6.3 (except for 
the collection of serum for s torage) until viremia is detected; at which time they will be 
instructed to restart cART and be followed  as outlined in Section 6.4.  
6.4 Follow -up  
Upon restarting cART, subject will enter the follow -up phase of the study. After 
restarting cART, s ubjects will be seen every 4 weeks  for 24 wee ks. At these visits, 
subjects will undergo the following procedures:  
• Medical history and a targeted physical exa mination, including weight, vital 
signs, and a symptom -directed evaluation based on symptoms or complaints 
reported by each participant  
• Assessment of concomitant medications  
• Assessme nt of any new or unresolved AEs or intercurrent illnesses  
• Neurological eva luation  screen  for signs and symptoms of PML . Any subjects 
that develop signs or symptoms suggestive of PML will be evaluated by a 
neurologist and undergo brain MRI and other workup as clinically indicated . 
• Blood collection for:  
o CBC with differential  
Protocol Version 5.0 
22-March-2017  
 
Page 29 of 53 
 o Chemistry panels, to include: ALT, AST, alkaline phosphatase, 
creatinine, total and direct bilirubin, and serum albumin levels  
o Flow cytometry panel (includes CD4+ T cell count)  
o Plasma HIV viral load  
o HIV genotype (performed  on all samples with viral levels ≥ 1,000 
copies/ml ) 
o Storage of plasma and PBMCs  
Management of cART during the follow -up period will be according to standard 
guidelines  (http://aidsinfo.nih.gov/guidelines ) 
 
7 Study Evaluations  
7.1 Clinical Evaluations  
 
• Medical history and physical examination  
• Phlebotomy: Blood will be collected for routine serologic, hematologic, and 
clinical chemistry evaluations as described in Section 6  
7.2 Laboratory Evaluations 
 Clinical and Research Laboratory Evaluations and Specimen 
Collection 
 
• HIV viral RNA levels  
• Flow cytometry with CD4+ T cell count  
• Serum for levels of vedolizumab  and antibody to vedolizumab  
 
Leukapheresis : Leukapheresis w ill be performed for research studies including, 
but not limited to, measurements of the  frequency of CD4+ T cells carrying 
replication -competent HIV by quantitative co -culture assays. These studies will 
address the exploratory endpoints. If leukapheresis cannot be performed for 
technical reasons (e.g. poor venous access) , 80 ml of blood will be drawn 
instead.  
Other research evaluations measuring the effect of vedolizumab on the HIV 
pathogenesis may include:  
 
• Frequency of CD4+ T cells carrying HIV pro -viral DNA and cell -
associated HIV RNA  
• Frequency of HIV -specific CD4+ and CD8+ T cells  
• T- cell activation and soluble markers of inflammation  
Protocol Version 5.0  
22-March -2017 
 
Page 30 of 53 
 • Residual (1 -40 copies/mL) plasma viremia  
• Gene expression profiling of T cells  
• Immunophenotypic profiling of PBMC s 
 
8 Potential Risks and Benefits  
8.1 Potential Risks  
 
 
Vedolizumab  
The identified and potential risks of vedolizumab IV treatmen t listed in this section have 
been assessed during the course of  controlled and open label  clinical studies . 
 
Identified Risks  
 
Infusion -Related Reactions  
In the completed 52 -week controlled studies in subjects with UC or CD , 4% of 
vedolizumab treated  subjects and 3% of placebo -treated subjects experienced infusion -
related reactions as  defined by the  investigator39,40. The majority of reactions  were mild 
or moderate in intensity and <1%  resulted in discontinuation of study treatment. 
Observed infusion -related reactions  generally resolved with no or  minimal intervention 
following the infusion .  Most reactions  were not serious and occurred during the infusion 
or within the first hour after  infusion was completed.  
 
 
Upper Respiratory Tract Infections  
Nasopharyngitis and upper respiratory tract infections are som e of the most common 
infectious treatment emergent AE seen across the clinical studies  of vedolizumab . In 
the Phase III  studies39,40, there was an overall rate of upper respiratory tract infection of 
24% in vedolizumab -treated subjects  compare d with 17% in the placebo -treated 
subjects  (see Section 1.1.3) . The most commonly reported diagnosis  included  
nasopharyngitis, upper respiratory tract infection, pharyngitis, and sinusitis.  
 
 
Potential Risks of Vedolizumab Treatment  
 
Serious Infections, Including Opportunistic Infections  
In the completed 52 -week controlled studies in subjects with U C or CD, the rate of 
infections was 0.85 per patient -year in vedolizumab -treated subjects and 0.70 per 
patient -year in placebo  treated  subjects. Th e infections consisted primarily of 
nasopharyngitis, upper respiratory tract  infection, sinusitis, and urinary tract infections. 
Most subjects continued on vedolizumab after  the infection resolved.  In the complet ed 
52-week controlled studies39,40, the rate of serious infections was 0.07 per patient  year 
in vedolizumab -treated subjects and 0.06 per patient -year in placebo -treated subjects. 
Over  time, there was no significant increase in the rate of serio us infections.  
 
In controlled and open -label studies in adults treated with vedolizumab, ser ious 
Protocol Version 5.0  
22-March -2017 
 
Page 31 of 53 
 infections have been reported, which include tuberculosis , sepsis, salmonella sepsis, 
Listeria meningitis, and  cytomegaloviral colitis.  
 
Natalizumab, another integrin receptor antagonist, has been associated with PML, a 
rare and often fatal opportunistic infection of the CNS41. PML is caused by the John 
Cunningham  virus (JCV) and typically only occurs in patients who are 
immunocompromised. Natalizumab is a pan -4 integrin antagonist that binds to both 
the α4β1 and α4β7 integrins and  inhibits cellular adhesion to V CAM -1 and MAd CAM -
142. In contrast, vedolizumab binds  to the α4β7 integrin only  and inhibits adhesion to 
MAdCAM -1, but not VCAM -143. Although  no cases of PML have been reported in 
clinical studies or post -marketing experience w ith vedolizumab to date  (over 11,943 
patient -years) , a risk of PML cannot be ruled out.  
 
 
Analytical treatment interruption  
The risks from an ATI, performed under close virologic  and immunological monitoring 
are minimal in this subject population. There is a theoretical risk that ATI could lead to 
the development of HIV drug resistance. This may be a particular concern for 
individuals taking NNRTIs. However, this potential risk wi th NNRTIs is essentially 
eliminated by undertaking the procedures described in Section  3.144. Given the study 
population, the frequency of immunological and virologic  monitoring, and strict criteria 
for restarting cART, it is extremely unlik ely that the ATI will lead to the development of 
any opportunistic infections or AIDS -defining conditions.  
 
During the ATI phase, subjects may transmit HIV infection if they do not adhere to safe 
sex practices.  
 
Phlebotomy /Insertion of IV Catheter   
This may be associated with discomfort, bruising, local hematoma formation and, on 
rare occasions, infections, lightheadedness, and fainting.  
 
The amount of blood drawn for research purposes will be within the limits allowed for 
adult subjects by the NIH  Clinical Center  (CC) (Medical Administrative Policy 95 -9: 
Guidelines for Limits of Blood Drawn for Research Purposes in the Clinical Center:  
http://cc -internal.cc.nih.gov/policies/PDF/M95 -9.pdf ). 
 
 
HLA typing  
Some HLA types have been associated with an inc reased risk of certain diseases like 
arthritis and other rheumatologic disorders, or a faster progression to AIDS. HLA 
typing will be performed on samples collected from all the enrolled subjects. Results 
from the HLA typing will become part of each subjec t’s medical record at the NIH. 
Medical records containing this information are maintained in a secure  place.  
8.2 Potential Benefits  
The possibility of  vedolizumab -induced sustained  control of HIV viremia in the 
absence of daily cART is a potential benefit from study participation. In addition, 
Protocol Version 5.0  
22-March -2017 
 
Page 32 of 53 
 others may benefit from knowledge gained in this study that may aid in the 
development  better  HIV treatments . 
 
9 Research Use of Stored Human Samples, Specimens , or 
Data  
 
• Intended Use: Stored blood samples and data collected under this protocol may 
be used to study the effect of vedolizumab on the virologic and immunologic 
parameters listed in Section 7.2.1. Samples may be used to study other aspects 
of the immunopathogenesis of HIV infe ction or measure serum levels of 
vedolizumab and antiretr oviral agents . Coded samples and demographic data 
will be sent to Takeda -Millennium Pharmaceuticals and its vendor, QPS for PK 
and immunogenicity studies.  
• Storage:  Access to stored samples will be l imited using a locked room or a 
locked freezer. Samples and data will be stored using codes assigned by the 
investigators. Data will be kept in password -protected computers. Only 
investigators will have access to the samples and data.  
 
• Tracking: Samples wi ll be tracked utilizing the NCI at Frederick Central 
Repository . Data will be stored and maintained in the NIAID CRIMSON 
database.  
 
• Disposition at the Completion of the Protocol: At the completion of the 
protocol (termination), samples and data will either be destroyed, or after IRB 
approval, transferred to another existing protocol.  
 
• Reporting the Loss or Destruction of Samples/Specimens/Data to the IRB:  
o Any loss or unanticipated  destruction of samples or data (for example, 
due to freezer malfunction) that meets the definition of Protocol 
Deviation and/or compromises the scientific integrity of t he data 
collected for the study,  will be reported to the NIAID IRB.  
o Subjects may decide at any point not to have their samples stored.  In 
this case, the principal investigator will destroy all known remaining 
samples and report what was done to both the subject and to the IRB.  
This de cision will not affect the subject’s participation in this protocol or 
any other protocols at NIH (If applicable) . 
10 Remuneration Plan for Subjects  
Eligible subjects will be compensated for travel according to the NIAID/NIH travel 
policy. Subjects will rece ive financial compensation for time and inconvenience 
according to the NIH C C volunteer guidelines: screening ($50), 2-pass 
leukapheresis ($200 for a procedure ; $50 for unsuccessful apheresis attempts ), 
research blood draw ($40), clinic visits ($30), vedol izumab infusion ($80).   If 
subject does not qualify or declines leukapheresis, an additional 80 mL research 
blood will be drawn and subject may be compensated an additional $25 for 
inconvenience.  
 
Protocol Version 5.0  
22-March -2017 
 
Page 33 of 53 
 11 Assessment of Safety  
11.1 Documenting, Recording, and Reporting Adverse Events  
At designated visits with the subject, information regarding AEs will be elicited 
by appropriate questioning and examinations, and it will be:  
• Immediately documented in the electronic database and medical record.  
• Reported as outlined below  (e.g., IND sponsor, IRB, Food and Drug 
Administration [FDA]).  
11.2 Definitions  
Adverse event (AE) 
An AE is any untoward or unfavorable medical occurrence in a human subject, 
including any abnormal sign (e.g., abnormal physical exam or laboratory 
finding), symptom, or disease temporally associated with the subject’s 
participation in the research, whether or not considered related to the 
research.  
 
Adverse reaction (AR)  
An adverse reaction (AR) is an AE that is caused by an investigational agent 
(drug or biologic).  
 
Suspected adverse reaction (SAR)  
A suspected AR (SAR) is an AE for which there is a reasonable possibility that 
the investigational agent caused the AE. ‘Reasonable possibility’ means that 
there is evidence to sug gest a causal relationship between the drug and the 
AE. A SAR implies a lesser degree of certainty about the causality than an 
AR, which implies a high degree of certainty.  
 
Serious adverse event  (SAE)   
An SAE is an AE that results in one or more of the fo llowing  outcomes:  
• Death  
• A life -threatening (i.e., an immediate threat to life) event  
• An inpatient hospitalization or prolongation of an existing hospitalization  
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct norm al life functions  
• A congenital anomaly/birth defect  
• A medically important event*  
*Medical and scientific judgment should be exercised in deciding whether 
expedited reporting is appropriate in other situations, such as important medical 
events that may not  be immediately life threatening or result in death or 
hospitalization, but they may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed above.  
 
Unexpected adverse event  
An AE is unexpected if it is not listed in the investigator’s brochure  or package  
insert (for marketed products), or it is not listed at the specificity or severity 
that has been observed. It is the responsibility of the IND sponsor to make this 
determination.  
 
Protocol Version 5.0  
22-March -2017 
 
Page 34 of 53 
 Serious and unexpected sus pected adverse reaction  
A serious and unexpected suspected AR (SUSAR) is a SAR that is both 
serious and unexpected.   
 
Unanticipated problem  
An unanticipated problem (UP) is an event, incident, experience, or outcome 
that is —  
1. Unexpected in terms of natu re, severity, or frequency in relation to — 
a. The research risks that are described in the IRB -approved research 
protocol and informed consent document; investigator’s brochure, or 
other study documents; and  
b. The characteristics of the subject population being  studied; and  
2. Related  or possibly  to participation in the research; and  
3. Suggests the research p laces subjects or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was 
previously known or recognized (per the  IND sponsor, an AE with a 
serious outcome will be considered increased risk).  
 
Unanticipated problem that is not an adverse event  
An unanticipated problem that is not an AE is  an incident, experience, or 
outcome that is not associated with an AE, which m eets the 3 criteria of a UP. 
Examples include breaches of confidentiality, accidental destruction of study 
records, and unaccounted -for study drug.  
 
Protocol Deviation  
Any change, divergence, or departure from the IRB approved study 
procedures in a research protocol. Protocol deviations are designated as 
serious or non -serious and further characterized as:  
 
• Those that occur because a member of the research team deviates from the 
protocol  
• Those that are identified before they occur, but cannot be prevented  
• Those that are discovered after they occur  
 
 
Serious Protocol Deviation:  A deviation that meets the definition of a 
Serious Adverse Event or compromises the safety, welfare or rights of 
subjects or others.  
 
Non-compliance: The failure to comply w ith applicable NIH HRPP policies, 
IRB requirements, or regulatory requirements for the protection of human 
subjects. Non -compliance is further characterized as:  
1. Serious: Non -compliance that  
a. Increases risks, or causes harm, to participants  
b. Decreases potenti al benefits to participants  
c. Compromises the integrity of the NIH -HRPP  
d. Invalidates the study data  
2. Continuing: Non -compliance that is recurring  
3. Minor: Non -compliance that, is neither serious nor continuing.  
Protocol Version 5.0 
22-March-2017  
 
Page 35 of 53 
 Protocol specified events 
Protocol specified events  are AEs specified in the protocol that the principal 
investigator, IND sponsor, or medical monitor would like to review in real time 
rather than weeks or months later, when they would otherwise appear in 
various line listings. These events may or may not also be SAEs.  
11.3 Investigator Assessment of Adverse Events  
If a diagnosis is clinically evident (or subsequently determined), the diagnosis rather than the individual signs and symptoms or lab abnormalities will be 
recorded as the AE.  
 
All AEs occurring from the time when the first infusion  is administered through 
the specified study follow -up period  will be documented, recorded, and 
reported. The principal investigator will evaluate all AEs with respect to 
Seriousness  (criteria listed a bove), Severity (intensity or grade), and 
Causality  (relationship to study agent and relationship to research) according 
to the following guidelines.  
 Severity  
The principal investigator will grade the severity of each AE according to the Division of Aids Table for Grading the Severity of Adult and Pediatric 
Adverse Events Version 2.0, November, 2014, which can be found at   
 
http://rsc.tech -
res.com/Document/safetyandpharmacovigilance/DAIDS_AE_GRADING_T
ABLE_v2_NOV2014.pdf  
 Causality    
Causality (likelihood that the event is related to the study agent) will be 
assessed considering the factors listed under the following categorie s:  
 
Definitely related     
• Reasonable temporal relationship  
• Follows a known response pattern  
• Clear evidence to suggest a causal relationship  
• There is no alternative etiology  
 
Probably related  
• Reasonable temporal relationship  
• Follows a suspected response pattern (based on similar agents)  
• No evidence of a more likely alternative etiology  
 
Possibly related   
• Reasonable temporal relationship  
• Little evidence for a more likely alternative etiology  
 
Unlikely related   
• Does not have a reasonable temporal relationship  
OR 
• Good evidence for a more likely alternative etiology  
Protocol Version 5.0 
22-March-2017  
 
Page 36 of 53 
  
Not related   
• Does not have a temporal relationship           
OR 
• Definitely due to an alternative etiology  
 
Note:    
Other factors (e.g., dechallenge, rechallenge) should also be considered for each causality category when appropriate. Causality assessment is based 
on available information at the time of the assessment of the AE. The 
investigator may revise the causality assessment as additional information 
becomes available.  
11.4 Inves tigator Reporting Responsibilities to the Sponsor  
   Adverse Events  
Line listings, frequency tables, and other summary AE data will be submitted to the IND sponsor per the Safety Review and Communications 
Plan (SRCP – see below), or as needed for periodic safety assessments, 
review of IND annual reports, review of IND safety reports, and preparation 
of final study reports.  
   Serious Adverse Events  
SAEs (whether or not they are also UPs) must be reported on the SAE/UP 
report form and sent to  the sponsor Clinical Safety Office (CSO) by fax or e -
mail attachment. Deaths and immediately life -threatening SAEs must be 
reported within 1 business day after the site becomes aware of the event. 
All other SAEs must be reported within 3 business days of site awareness.  
 
Sponsor clinical safety office contact information:  
OCRPRO Clinical Safety Office  
5705 Industry Lane  
Frederick, MD 21704  
 
Phone 301 -846-5301  
Fax 301- 846-6224  
E-mail: rchspsafety@mail.nih.gov   
   Unanticipated Problems 
Non-serious AEs that are UPs must also be reported on the SAE/UP report 
form and sent  to the CSO by fax or e -mail attachment no later than 7 
calendar days of site awareness of the event. UPs that are not AEs are not 
reported to the sponsor CSO.  
   Protocol Specified Events  
Opportunistic infections  are AEs of special interest . These protocol 
specified events must be reported to the CSO on a SAE/UP report form 
within 3 business days of site awareness.    
Protocol Version 5.0 
22-March-2017  
 
Page 37 of 53 
 
   Pregnancy 
Pregnancy itself is not an AE. However, complications of pregnancies are 
AEs and may be SAEs. Pertinent obstetrical information for all pregnancies, 
including pregnancies disclosed by the subject as occurring in a partner of 
a male subject, will be reported to the CSO via fax or e -mail within 3 
business days from the site awareness of the pregnancy.   
 
Pregnancy outcome data (e.g., delivery outcome, spontaneous or elective 
termination of the pregnancy) will be reported to the CSO within 3 business 
days of the site awareness on a protocol -specified form. In the event of 
pregnancy, the following steps will be taken:  
• Discontinuation of the study agents  
• Withdraw from the study but continue following for safet y 
• Report to Medical Monitor  and the IRB  
• Advise research subject to notify the obstetrician of study agent 
exposure  
11.5 Investigator Reporting Responsibilities to the NIAID IRB   
   Expedited Reporting to the NIAID IRB  
Serious and non -serious Unanticipated Problems, deaths, serious 
deviations, and serious or continuing non -compliance will be reported 
within 7 calendar days of investigator awareness. SAEs that are possibly, 
probably, or definitely related to the research will be reported to the NIAID 
IRB within 7 calendar days of investigator awareness, regardless of expectedness.  
 
12.5.1.1.  Waiver of Reporting Anticipated Protocol Deviations, Expected UP nonAEs and Deaths to the NIAID IRB  
 Anticipated deviations in the conduct of the protocol w ill not be 
subject to expedited  reporting  to the IRB unless they occur at a rate 
greater than anticipated by the study team. Expected adverse events will not be reported to the IRB unless they occur at a rate 
greater than that known to occur in HIV(+) population. If the rate of 
these events exceeds the rate expected by the study team, the 
events will be classified and reported as though they are unanticipated problems . 
   Annual Reporting to the NIAID IRB   
The following items will be reported to the NIAID IRB in summary at the time of continuing review:  
• Serious and non -serious unanticipated problems  
• Expected serious adverse events that are possibly, probably, or definitely related to the research  
• Serious adverse events that are not related to the research  
• All adverse events, except expected AEs and deaths granted a 
waiver of reporting  
Protocol Version 5.0  
22-March -2017 
 
Page 38 of 53 
 • Serious and Non -Serious Protocol deviations . Anticipated 
deviations in the conduct of the protocol will not be reported to the 
IRB unless they occur at a rate greater than an ticipated by the 
study team  
• Serious, continuing, and minor non -compliance  
▪ Any trends or events which in the opinion of the investigator should 
be reported  
11.6  Follow -up of Adverse Events and Serious Adverse Events  
AEs that occur following enrollment of subjec ts (i.e., after the first dose of 
vedolizumab ) are followed until the final outcome is  known or until the end of 
the study follow -up period.  
 
SAEs that  that are assessed by the investigator to be possibly, probably, or 
definitely related  to vedolizumab an d that have not resolved by the end of the 
follow -up period will be  followed until the final  outcome is known. If it is not 
possible to obtain a final outcome for an SAE (e.g.  the subject is lost to follow 
up), the reason a final outcome could not be obtained will be recorded by the 
investigator on the SAE/UP report form.   
 
SAEs that occur after study completion that are reported to and are assessed 
by the investigator to be possibly, probably, or definitely related must be 
reported to the CSO, as desc ribed above.  
11.7 Sponsor’s Reporting Responsibilities  
SUSARs as defined in 21 Code of Federal Regulations (CFR) 312.32 and 
determined by the IND sponsor will be reported to the FDA and all 
participating investigators as IND safety reports.  
 
The IND sponsor wi ll also submit an IND annual report of the progress of the 
investigation to the FDA as defined in 21 CFR 312.33.  
11.8  Halting Criteria for the Protocol  
Halting the study requires immediate discontinuation of the study agents 
administered for all subjects and suspension of enrollment until a decision is 
made about whether or not to continue study agent administration.   
  
The halting criteria (as determine d by the study PI and IND sponsor secondary 
to aggregate data review) for this study include:  
• Any SAE or grade 4 AE that is possibly, probably, definitely related to the 
study agent; OR  
• Any safety issue that the study principal investigator  or IND sponsor 
determines should halt the study.  
• Pre-defined futility criteria for virologic failure are met (see Section 13).  
 
Any related AE that is ≥ grade 3 (not including transient, subjective infusion -
related symptoms such as malaise, fatigue, headache, chills) will be reviewed 
within 48 hours of site awareness, by the PI and IND sponsor medical monitor, 
Protocol Version 5.0 
22-March-2017  
 
Page 39 of 53 
 to consider the need for halting the protocol.  
 
The PI and/o r CSO w ill determine if the st udy should be halted. In addition, 
the FDA m ay ha lt the st udy at any time fo llowing review of any safe ty 
concerns.  
   Reporting of Study Halting  
If a halting ru le is met, a description of the adverse ev ent(s) o r safety issue must 
be reported by the P I, within one busi ness day, to the CSO and to the IRB by fax 
or email. The sponsor will notify the FDA as soon as possible that the study has 
been halted.  
 
   Resumption of a Halted Study 
The IND Sponsor, in collabo ration w ith the P I will determine if it is safe to resume the 
study. The PI w ill notify the IRB of the decision on resump tion of the st udy. The 
sponsor will notify the FDA as soon as possible that the study has been  resumed after 
a halt.  
11.9  Pausing Criteria for a Subject   
The decision to suspend administration of the study agent  for a single subject  requires 
discontinuation of the study agent administrated for the study subject  until a decision is 
made whether or not to continue study agent administration.   
 
The pausing criteria for a single subject in this study include:  
 
• A subject experience s an SAE or grade 3 or greater AE (not including 
transient, subjective infusion -related  symptoms such as malaise, fatigue, 
headache, chills, or total bilirubin in subjects taking atazanavir) that  is (as 
determined by the IND sponsor) possibly, probably, or definitely related  to 
the study agent;  
OR 
 
• Any safety issue that the PI determines should pause administration of the 
study agent to a single subject.  
 
The CSO , in collaboration with the PI, may also pause for an individual subject 
or the entire group if a safety concern is identified during routine aggregate 
data analysis.  
   Reporting of Pause If a pausing requirement is met, a description of the AE(s) or safety issue 
must be reported by the  PI by fax or e -mail within 1 business day to the 
sponsor CSO, principal investigator, IRB, and the Medical Monitor .  The 
sponsor will notify the FDA as soon as po ssible that the  study agent has 
been halted for an individual subject . 
   Resumption of Pausing for a Subject or Group 
Protocol Version 5.0 
22-March-2017  
 
Page 40 of 53 
 The CSO in co llaboration w ith the P I  will determine w hether or not it is safe 
to resum e administra tion of the st udy agent to the subje ct. The principal 
investigator will notify the IRB of the decision to resume administration of 
the study agent prior to resumption.  The sponsor will notify the FDA as 
soon as possible that the  study agent has been resumed  for an  individual 
subject.  
 
 
A sub ject who does not resume st udy ag ent wi ll continue to be fo llowed fo r 
safety. 
 
11.10   Withdrawal Criteria for an Individual Subject 
An individual subject will be withdrawn for any of the following:  
• An individual subject’s decision. (The PI will attempt to determine the 
reason for the subject’s decision, and will strongly suggest a follow -up plan 
to help ensure the subject safely returns to baseline or better, if possible).  
• Co-enrollment in a study with an investigational research agent (rare 
exception granted by the PI).  
• Any SAE or grade 4 systemic infusion related symptom(s) or AE that is 
considered to be related to the study agent.  
• Clinically significant type 1 hypersensitivity reaction associated with the 
study agent. In the event of a type 1 hypersensitivity reaction that is NOT 
considered to be clinically signif icant, (e.g., brief, mild, and self -limited skin 
reaction without other symptoms), the PI may consider possible additional 
infusions of the study agent  with appropriate precautions.  
• Any clinical AE, laboratory abnormality, or other medical condition or situation such that continued participation in the study would not be in the 
best interest of the subject. Subjects will be followed for the duration of the study for indicated safety assessments.  
• Non-compliance with study procedures to the extent that it is potentially 
harmful to the subject or to the integrity of the study data.  
• Pregnancy.  
• Participant misses more than 2 study infusions . 
 
If possible, all subjects who discontinue the study treatment prematurely will be followed for 6 months for all the study evaluations.  
11.11   Replacement for Withdrawn Subjects 
Any subject who withdraws from the study, or who discontinues the study 
agent, prematurely, and whose reasons for withdrawing from the study or 
discontinuing study agent  administration are unrelated to any real or perceived 
effect of the study agent  or their administration, will be replaced.  
11.12   Safety Oversight  
  Safety Review and C ommunications Plan (SRCP)  
Protocol Version 5.0 
22-March-2017  
 
Page 41 of 53 
 A Safety Review and Communication s Plan ( SRCP ) has been developed 
for the protocol. The SRCP is an internal communications document 
between the principal investigator and the IND sponsor CSO, which 
delineates the safety oversight responsibilities of the principal investigator , 
the CSO, and other stake holders. The SRCP also includes the overall plan 
for conducting periodic safety surveillance assessments.   
   Sponsor Medical Monitor  
A medical monitor, representing the IND sponsor (OCRPRO), has been 
appointed for the safety oversight in this clinical study. The sponsor medical 
monitor will be responsible for performing safety assessments as outlined in the SRCP.  
12 Clinical Monitoring Structure  
12.1 Site Monitoring Plan  
As per ICH -GCP 5.18 and FDA 21  CFR 312.50  clinical protocols are required 
to be adequately monitored by the study sponsor. This study monitoring will be conducted according to the  “NIAID Intramural Clinical Monitoring Guidelines ”. 
Monitors un der contract to the NIAID/
 OCRPRO  will visit the clinical research 
site to monitor aspects of the study in  accordance with the appropriate 
regulations and the approved protocol. The objectives of a monitoring visit will be: 1) to verify the existence of signed informed consent documents and documentation of the ICF process for each monitored subject; 2) to ver ify the 
prompt and accurate recording of all monitored data points, and prompt reporting of all SAEs; 3) to compare  CRIMSON data abstracts with individual 
subjects’ records and source documents (subjects’ charts, laboratory analyses 
and test results, physi cians’ progress notes, nurses’ notes, and any other 
relevant original subject information); and 4) to help ensure investigators’ are 
in compliance with the protocol. The monitors also will inspect the clinical site 
regulatory files to ensure that regulatory requirements (Office for Human 
Research Protections -OHRP , FDA ), and applicable guidelines (ICH -GCP) are 
being followed. During the monitoring visits, the investigator (and/or designee) 
and other study personnel will be available to discuss the study progress and 
monitoring visit.  
 
The investigator (and/or designee) will make study documents (e.g., consent 
forms, CRIMSON data abstracts , and pertinent hospital or clinical records 
readily available for inspection by the local IRB, the FDA , the site monitors, 
and the NIAID staff for confirmation of the study data.  
 
A specific protocol monitoring plan will be discussed with the Principal 
Investigator and study staff prior to enrollment. The plan will outline the 
frequency of monitoring visits based on such factors as study enrollment, data collection status and regulatory obligations.   
 
13 Statistical Considerations 
Protocol Version 5.0  
22-March -2017 
 
Page 42 of 53 
 The primary safety outcome i s the occurrence of grade 2 or higher adverse events.  An 
exact 95% confidence interval for the probability of adverse events will be computed 
using the Clopper -Pearson method.  The primary efficacy outcome is rebound of 
plasma viremia requiring a restart of cART.  An exact 95% confidence interval will be 
computed for the rebound probability using the Clopper -Pearson method.  Changes 
from baseline in continuous measurements will be analyzed using paired t -tests or, if 
data are skewed, the Wilcoxon signed ra nk statistic.      
 
In term s of safety, a sample size of 20 patients provides a 96.1% chance of observing 
an adverse event of probability 15 % or greater.  Table 1.1.3 -1 shows the chance of 
observing at least one adverse event of given probability.  
 
Table 13-1. The second row is the probability of observing at least one 
adverse event of probability given in the first row.  
0.025  0.050  0.075  0.100  0.125  0.150  
.397 .642 .790 .878 .931 .961 
 
 
The sample size for this study is 20 subjects with suppressed HIV viremia on cART. In 
the absence of a therapeutic intervention, it is expected that 100% of such subjects 
would experience a rebound in plasma HIV viremia; with a median time to rebound of 2 -
4 weeks11-13. Based on the pre -clinical primate studies described above, we would 
expect treatment with v edolizumab to significantly reduce the rate of viral rebound after 
discontinuation of cART. Table 13-2 shows the confidence interval for the probability of 
rebound for a sample size of 15 subjects.  Row 1 is the number of rebounds out of 15, 
and row 2 is the confidence interval.  
  
Table 13-2. The second row gives exact 95% confidence intervals for 
rebound probability given the observed number of rebounders in row 1 
among the 20 patients.   
0 2 4 6 8 10 12 14 16 18 20 
.000-
.168 .012-
.317 .057-
.437 .119-
.543 .191-
.640 .272-
.728 .360-
809 .457-
.881 .563-
.943 .683-
.988 .832-
1.00 
 
For example, if there are 6 rebounds, we can be quite confident that the true rebound 
probability is between . 119 and . 543.  
 
Futility guidelines are based on the nu mbers of patients meeting virologic criteria to 
restart cART prior to study week 30.   We use Bayesian methodology whereby we 
quantify our prior opinion about the 42 day probability with monoclonal antibodies as 
roughly equivalent to having observed 4 peopl e, 2 of whom meet virologic criteria to 
restart cART by 30 weeks .  This translates to a beta (2,2) prior distribution for p, the 
probability of meeting virologic criter ia of failure by 30 weeks .  Futility is declared if the 
posterior probability that p exceeds 0.70, given the observed results, is 90% or greater.  
The futility boundary is shown in Table 13 -3.  For example, the boundary is crossed if 
the first 9 patients rebound by 30 weeks.  Likewise, futility can be declared if 12 of the 
first 13 rebound by 30 weeks, etc . 
 
 
Protocol Version 5.0 
22-March-2017  
 
Page 43 of 53 
 Table 13-3 Futility is declared if the number of patients rebounding by 
week 30, among the number tested in row 1, is at least as large as the 
figure in row 2  
9 10 11 12 13 14 15 16 17 18 19 20 
9 10 11 12 12 13 14 15 16 16 17 18 
 
The probabilities of crossing this futility boundary are shown in Table 13-4 for different 
true probabilities.  
 
 
Table 13-4.  Row 2 shows the probability of crossing the futility threshold 
if the true 30 -week rebound probability is as shown in row 1.  
.50 .60 .70 .80 .90 .95 
.003 .021 .099 .339 .775 .953 
  
For instance, if the true 30 -week  probability of having plasma viral level > 1,000 is 0.50, 
the probability of crossing the futility boundary is only 0.00 3.  On the other hand, if the 
true 30- week  rebound probability is 0.9 5, the probability of crossing the futility boundary 
is 0.953 . 
 
14 Ethics/Protection of Human Subjects  
14.1 Informed Consent Process 
Informed consent is a process where information is presented to  enable 
persons to voluntarily decide whether or not to participate as a research 
subject. It is an on -going conversation between the human research subject 
and the researchers which begins before consent is given and continues until 
the end of the subject's involvement in the research. Discussions about the 
research will provide essential information about the study and include 
purpose, duration, experimental procedures, alternatives, risks , and benefits.  
Subjects will be given the opportunity to ask questions and have them 
answered.  
The subjects will sign the informed consent document prior to undergoing any 
research procedures. The subjects may withdraw consent at any time 
throughout the course of the trial.  A copy of the informed consent document 
will be given to the subjects for their records. The researcher will document the 
signing of the consent form in the subject’s medical record. The rights and 
welfare of the subjects will be protected by emphasizing to them that the quality 
of their medical care will not be adversely affected if they decline to participate 
in this study.  
 Non- English –Speaking Participants 
If a non- English speaking participant is unexpectedly eligible for enrollment, 
the participant will be provided with the CC Short Written Consent Form for 
Protocol Version 5.0  
22-March -2017 
 
Page 44 of 53 
 Non-English Speaking Research Participants in the participant’s native 
language and a verbal explanat ion of the purpose, procedures and risks of 
the study as described in MAS Policy M77 -2, NIH HRPP SOP 12 and 45 
CFR 46.117(b)(2) . The IRB -approved English consent form will serve as 
basis for the verbal explanation of the study. The investigator will obtain  an 
interpreter unless the investigator is fluent in the prospective participant’s 
language. Preferably, the interpreter will be someone who is independent of 
the participant (i.e., not a family member). Interpreters provided by the CC 
will be used wheneve r possible. The interpreters will translate the IRB -
approved English consent form verbatim and facilitate discussion between 
the participant and investigator.  
The IRB -approved English consent form will be signed by the investigator 
obtaining consent and a witness to the oral presentation. The CC Short 
Written Consent Form will be signed by the participant and a witness who 
observed the presentation of information. The interpreter may sign the 
consent document as the witness and, in this case, will note “Int erpreter” 
under the signature line. A copy of both signed forms will be provided to the 
participant to take home.  
The investigator obtaining consent will document the consent process in the 
participant’s medical record (CRIMSON) , including the name of the 
interpreter. Further, all instances of use of the CC Short Written Consent 
Form will be reported to the IRB at the time of annual review. If the CC 
Short Written Consent Form is used three times or more for the same 
language, this will be reported to the I RB immediately.  
 Illiterate English Speaking Participants  
As the majority of the patient populations from which the study participants 
are drawn are literate, written consent will typically be provided.  However, 
this population does have a significant rate of illiteracy, and oral consent will 
be obtained for illiterate participants as consistent with NIH  Medical 
Administrative Services  (MAS ) Policy M77 -2 without separate IRB approval 
for each specific use. At Continuing Reviews, the NIAID IR B will be 
informed of the number of illiterate participants who provided consent 
verbally.  
14.2 Subject Confidentiality  
All records will be kept confidential to the extent provided by federal, state , and 
local law. The study monitors and other authorized repres entatives of the 
Sponsor may inspect all documents and records required to be maintained by 
the Investigator, including but not limited to, medical records.  Records will be 
stored in a  locked  area, and all computer entry and networking programs will  
use coded numbers only.  Clinical information will not be released without 
written permission of the subject, except as necessary for monitoring by IRB, 
FDA, NIAID,  OHRP, Takeda, or the sponsor’s designee.  
15 Data Handling and Record Keeping  
15.1 Data Capture and Manag ement  
Protocol Version 5.0  
22-March -2017 
 
Page 45 of 53 
  
Study data will be maintained in CRIMSON and collected directly from subjects 
during study visits and telephone calls, or will be abstracted from subjects’ 
medical records. Source documents include all recordings of observations or 
notations of cli nical activities and all reports and records necessary to confirm 
the data abstracted for this study. Data entry into CRIMSON will be performed 
by authorized individuals. The Investigator is responsible for assuring that the 
data collected are complete, ac curate, and recorded in a timely manner.  
 
15.2 Record Retention  
 
The investigator is responsible for retaining all essential documents listed in the 
ICH Good Clinical Practice Guideline.  Study records will be maintained by the 
PI for a minimum of 3 years and i n compliance with institutional, IRB, state, and 
federal medical records retention requirements, whichever is longest. All stored 
records will be kept confidential to the extent required by federal, state, and 
local law.  
 
Should the investigator wish to as sign the study records to another party and/or 
move them to another location, the investigator will provide written notification 
of such intent to  OCRPRO /NIAID with the name of the person who will accept 
responsibility for the transferred records and/or th eir new location. Destruction 
or relocation of research records will not proceed without written permission 
from NIAID/RCHSPB.  
Protocol Version 5.0  
22-March -2017 
 
Appendix A: Scientific References  
 
1. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV 
infection. Lancet 2010;376:49 -62. 
2. Chun TW, Davey RT, Jr., Engel D, Lane HC, Fauci AS. Re -emergence of HIV 
after stopping therapy. Nature 1999;401:874 -5. 
3. Chun TW, Fauci AS. HIV reservoirs: pathoge nesis and obstacles to viral 
eradication and cure. AIDS 2012;26:1261 -8. 
4. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients 
receiving antiretroviral therapy for extended periods: implications for eradication of virus. 
J Infect D is 2007;195:1762 -4. 
5. Chun TW, Nickle DC, Justement JS, et al. HIV -infected individuals receiving 
effective antiviral therapy for extended periods of time continually replenish their viral 
reservoir. J Clin Invest 2005;115:3250 -5. 
6. Chun TW, Stuyver L, M izell SB, et al. Presence of an inducible HIV -1 latent 
reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 
1997;94:13193 -7. 
7. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV -1 in 
patients on highl y active antiretroviral therapy. Science 1997;278:1295 -300. 
8. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication -competent HIV 
despite prolonged suppression of plasma viremia. Science 1997;278:1291 -5. 
9. Buzon MJ, Massanella M, Llibre JM, et al. HIV -1 replication and immune 
dynamics are affected by raltegravir intensification of HAART -suppressed subjects. Nat 
Med 2010;16:460 -5. 
10. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir -containing 
intensification on HIV burden and T -cell activation in multiple gut sites of HIV -positive 
adults on suppressive antiretroviral therapy. AIDS 2010;24:2451 -60. 
11. Davey RT, Jr., Bhat N, Yoder C, et al. HIV -1 and T cell dynamics after 
interruption of highly active antiretroviral therapy (HAART) in  patients with a history of 
sustained viral suppression. Proc Natl Acad Sci U S A 1999;96:15109 -14. 
12. Rothenberger MK, Keele BF, Wietgrefe SW, et al. Large number of 
rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues 
after treatment interruption. Proc Natl Acad Sci U S A 2015;112:E1126 -34. 
13. Steingrover R, Pogany K, Fernandez Garcia E, et al. HIV -1 viral rebound 
dynamics after a single treatment interruption depends on time of initiation of highly 
active antiretroviral  therapy. AIDS 2008;22:1583 -8. 
14. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific 
strategy. Nat Rev Immunol 2012;12:607 -14. 
15. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin -2 on the pool of latently 
infected, r esting CD4+ T cells in HIV -1-infected patients receiving highly active anti -
retroviral therapy. Nat Med 1999;5:651 -5. 
16. Prins JM, Jurriaans S, van Praag RM, et al. Immuno -activation with anti -CD3 and 
recombinant human IL -2 in HIV -1-infected patients on p otent antiretroviral therapy. AIDS 
1999;13:2405 -10. 
17. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV -1 infection in vivo: 
a proof -of-concept study. Lancet 2005;366:549 -55. 
18. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vor inostat disrupts 
HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482 -5. 
19. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T 
cells of persons infected with HIV. N Engl J Med 2014;370:901 -10. 
Protocol Version 5.0  
22-March -2017 
 
Page 47 of 53 
 20. Hutter G, Nowa k D, Mossner M, et al. Long -term control of HIV by CCR5 
Delta32/Delta32 stem -cell transplantation. N Engl J Med 2009;360:692 -8. 
21. Burton DR, Ahmed R, Barouch DH, et al. A Blueprint for HIV Vaccine Discovery. 
Cell Host Microbe 2012;12:396 -407. 
22. Fauci A S, Marston HD. Ending AIDS --is an HIV vaccine necessary? N Engl J 
Med 2014;370:495 -8. 
23. Moir S, Malaspina A, Fauci AS. Prospects for an HIV vaccine: leading B cells 
down the right path. Nat Struct Mol Biol 2011;18:1317 -21. 
24. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by 
multiple highly potent antibodies. Nature 2011;477:466 -70. 
25. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent 
neutralization of HIV -1 by antibody VRC01. Science 2010;329:811 -7. 
26. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent 
neutralizing HIV -1-specific monoclonal antibodies in SHIV -infected rhesus monkeys. 
Nature 2013;503:224 -8. 
27. Klein F, Halper -Stromberg A, Horwitz JA, et al. HIV therapy by a com bination of 
broadly neutralizing antibodies in humanized mice. Nature 2012;492:118 -22. 
28. Shingai M, Nishimura Y, Klein F, et al. Antibody -mediated immunotherapy of 
macaques chronically infected with SHIV suppresses viraemia. Nature 2013;503:277 -80. 
29. Malbec M, Porrot F, Rua R, et al. Broadly neutralizing antibodies that inhibit HIV -
1 cell to cell transmission. J Exp Med 2013;210:2813 -21. 
30. Arthos J, Cicala C, Martinelli E, et al. HIV -1 envelope protein binds to and signals 
through integrin alpha4beta7 , the gut mucosal homing receptor for peripheral T cells. 
Nat Immunol 2008;9:301 -9. 
31. Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a 
complex with cell -surface CD4 and defines a T -cell subset that is highly susceptible to 
infection by HIV -1. Proc Natl Acad Sci U S A 2009;106:20877 -82. 
32. Byrareddy SN, Kallam B, Arthos J, et al. Targeting alpha4beta7 integrin reduces 
mucosal transmission of simian immunodeficiency virus and protects gut -associated 
lymphoid tissue from infection . Nat Med 2014;20:1397 -400. 
33. Haanstra KG, Hofman SO, Lopes Estevao DM, et al. Antagonizing the 
alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central 
nervous system in rhesus monkey experimental autoimmune encephalomy elitis. J 
Immunol 2013;190:1961 -73. 
34. Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut 
homing alpha4beta7 integrin, does not affect cerebrospinal fluid T -lymphocyte 
immunophenotype. J Neuroimmunol 2013;264:123 -6. 
35. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to 
immunisation selectively in the gastrointestinal tract: randomised controlled trial results. 
Gut 2015;64:77 -83. 
36. Wyant T, Estevam J, Yang L, Rosario M. Development and validation of rec eptor 
occupancy pharmacodynamic assays used in the clinical development of the monoclonal 
antibody vedolizumab. Cytometry B Clin Cytom 2015.  
37. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active 
ulcerative colitis: a randomized con trolled phase 2 dose -ranging study. Inflamm Bowel 
Dis 2012;18:1470 -9. 
38. Pereira LE, Onlamoon N, Wang X, et al. Preliminary in vivo efficacy studies of a 
recombinant rhesus anti -alpha(4)beta(7) monoclonal antibody. Cell Immunol 
2009;259:165 -76. 
39. Feagan  BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and 
maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699 -710. 
Protocol Version 5.0  
22-March -2017 
 
Page 48 of 53 
 40. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and 
maintenance therapy for Crohn's disease.  N Engl J Med 2013;369:711 -21. 
41. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with 
natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 
2006;354:924 -33. 
42. Miller DH, Khan OA, Sheremata WA, et al. A con trolled trial of natalizumab for 
relapsing multiple sclerosis. N Engl J Med 2003;348:15 -23. 
43. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding 
specificity and selective antagonism of vedolizumab, an anti -alpha4beta7 integrin 
therapeuti c antibody in development for inflammatory bowel diseases. J Pharmacol Exp 
Ther 2009;330:864 -75. 
44. Spartac Investigators. Short -course antiretroviral therapy in primary HIV infection. 
N Engl J Med 2013;368:207 -17. 
Protocol Version 5.0  
22-March -2017 
 
Appendix B : Schedule of Procedures/Evaluations  
 Screening and Baseline  ART Phase  
Study Time Point  Screen  Apher 
esis Base 
line Opt. 
Day 
3 Opt. 
Week 
1 Week 
2 Week 
6 Week 
10 Apher 
esis Week 
14 Week 
18 Apher 
esis Week 
22 Week 
24 Week 
26 Week 
28 Week 
30 
ASSESSMENTS                   
Consent  X                 
Vital Signs  X  X   X X X  X X  X  X  X 
H & P  X  X   X X X  X X  X  X  X 
HIV Counseling    X   X X X  X X  X  X  X 
PML Checklist    X   X X X  X X  X  X  X 
Neurologic Exam    X   X X X  X X  X  X  X 
MEDICATIONS                   
Last Dose of 
cART              X     
vedolizumab 
Infusion    X   X X X  X X  X  X  X 
Restart cART               PRN  PRN  PRN  PRN  
PROCEDURES                   
EKG  X                 
Leukapheresis   X       X   X      
CLINICAL LABS                   
CBC/Diff  X  X   X X X  X X  X  X  X 
aPTT/PT  X                 
Acute/Hepatic/  
/Mineral  X  X   X X X  X X  X  X  X 
Urinalysis  X                 
Pregnancy*  X X X   X X X X X X X X  X  X 
Anti-HBs, Anti -
HAV, HBsAg, 
Anti-HCV, HCV 
RNA , 
QuantiFERON  X                 
HLA Typing**    X               
RESEARCH 
LABS                   
HIV-1 RNA  X  X   X X X  X X  X X X X X 
Flow 
Cytometry***  X  X   X X X  X X  X X X X X 
Serum storage  X  X X X  X X  X X  X  X  X 
Plasma storage  X  X X X X X X  X X  X X X X X 
PBMCs storage     X   X X X  X X  X  X  X 
PAXgene RNA 
TWC (Opt.)    X X X X X           
Estimated 
Volume per Visit  61  126 31 31 108 116 113  113 113  113 30 113 30 113 
 
Protocol Version 5.0  
22-March -2017 
 
Page 50 of 53 
 Appendix B continued  
 ATI Phase  Follow -up Phase  
Study Time Point  Week 
32 Week 
34 Week 
36 Weeks 
38-48 Repeat - 
End ATI  cART 
Start  Week 
4 Week 
8 Week 
12 Week 
16 Week 
20 Week 
24 
ASSESSMENTS              
Consent    
 
Continue Schedule of Procedures          
Vital Signs   X    X X X X X X 
H & P   X  PRN   X X X X X X 
HIV Counseling   X          
PML Checklist             
Neurological 
Evaluation   X    X X X X X X 
MEDICATIONS             
Last Dose of 
cART             
Vedolizumab 
Infusion             
Restart cART  PRN  PRN  PRN  PRN  X       
PROCEDURES             
EKG             
Leukapheresis             
CLINICAL LABS             
CBC/Diff   X    X X X X X X 
aPTT/PT             
Acute/Hepatic/Mi
neral   X    X X X X X X 
Urinalysis             
Pregnancy*   X          
Anti-HBs, Anti -
HAV, HBsAg, 
Anti-HCV, HCV 
RNA     
  
      
RESEARCH 
LABS             
HIV-1 RNA  X X X PRN   X X X X X X 
Flow 
Cytometry**  X X X PRN   X X X X X X 
Serum storage 
(Opt)    X         
Plasma storage  X X X PRN   X X X X X X 
PBMCs storage   X X   X X X X X X 
Estimated 
Volume Per Visit  30 113 38 10-PRN   97 97 97 97 97 97 
* for women of childbearing potential    PRN: as needed depending on when subject meets criteria to restart cART  
 ** if not already on file              
***includes CD4+ T cell  count  
Protocol Version 5.0  
22-March -2017 
 
Appendix C: PML Checklis t 
▪ This c hecklist will be a dminister ed at specified visits as outlined in the schedule of 
events in the protocol and ad hoc for patient reported symptoms.  
▪ The purpose of this checklist is to identify a definite change in the patient’s 
neurological status from the previous evaluation.  
▪ For all positive subjective findings that are identified, the corresponding objective test 
must be performed . All positive subjective findings will be recorded as  an adverse 
event.  
▪ Subjects with  a definite change in neurological status  will be referred to  a neurologist 
for evaluation . Where possible, the proposed objective tests  will be used  to confirm a 
change that warrants referral.  
 
Protocol Version 5.0  
22-March -2017 
 
Page 52 of 53 
 Subjective PML Checklist  
Symptoms  “Compared to how 
you usually feel, 
have you had a 
significant change 
in any of the 
following? ” If the answer is 
"Yes", obtain a 
description of the 
symptom(s) with 
examples.  Applicable  
Objective Test(s):  
Document results on PML 
Objective Checklist  
 Yes No   
1. Have you been 
experiencing any persistent 
difficulty with your vision 
such as loss of vision or 
double vision?  Have you 
been having trouble with 
reading?      Test visual fields and ocular 
motility.  
 
2. Have you been 
experiencing any persistent 
difficulty speaking or having 
your speech understood by 
others?     Casual observation of speech 
output for dysarthria or 
aphasia.  Ask  subject  to name 
a few objects and repeat a 
multipart phrase.  
3. Have you been 
experiencing any persistent 
weakness in an arm or a 
leg?    Test for pronator drift (Barré 
maneuver) and/or fixation on 
arm roll.  Assess the ability to 
hop on either foot  and foot and 
finger tapping. Test symmetric 
muscle strength.  
4. Have you noticed yourself 
regularly bumping into things 
or having difficulty writing ?    Ask for spontaneous writing 
sample . Observe finger to 
nose, heel to shin, and tandem 
gait. 
5. Have you r egularly been  
experiencing difficulty 
understanding others?     Test subject’s a bility to follow 
serial commands (Close your 
eyes ; stick out your tongue , 
and touch your left finger to 
your left ear) . 
6.  Have you had persistent  
problems with your memory  
or thinking?     Test subject’s ability to r ecall 3 
objects over 1 minute with 
distraction  and ability to follow 
commands.  
7.  Have you been 
experiencing any persistent 
numbness or other loss of 
sensation?     Test sensation side to side 
with pinpric k. 
 
      
Protocol Version 5.0  
22-March -2017 
 
Page 53 of 53 
 Objective PML Checklist  
To be completed for  subjects  with positive subjective finding 
Perform the objective test(s) that correspond to the subjective checklist finding  
 
 
 
 
 
 
 
 
 Positive 
Symptom(s)  Applicable Objective Test(s)  
Test Result(s)  If test result is abnormal, 
briefly describe result  
  Normal  Abnormal   
1. Difficulty 
with vision or 
reading  Test visual fields and ocular 
motility     
2. Difficulty 
with speaking  Casual observation of speech 
output for dysarthria or aphasia.    
Ask patient to name a few 
objects and repeat a multipart 
phrase.     
3. Weakness in 
an arm or a leg  Test for pronator drift and/or 
fixation on arm roll.  Assess the 
ability to hop on either foot; foot 
and finger tapping.  Test muscle 
strength.     
4. Bumping 
into things or 
difficulty writing  Ask for spontaneous written 
sample and observe finger to 
nose, heel to shin, and ta ndem 
gait    
5. Difficulty 
understanding 
others  Ability to follow serial commands 
(Close your eyes, stick out your 
tongue, and tou ch your left finger 
to your left ear)     
6.  Problems 
with memory or 
thinking  Recall of 3 objects over 1 minute 
with distraction; ability to follow 
commands.     
7. Problems 
with numbness  Test sensation side to side with 
pinprick.     